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ABSTRACT
Title: The prevalence of polymorphism of exon 3 expression of the growth hormone 
receptor gene in the general population and its influence on the quality of life, body 
composition and response to growth hormone replacement in growth hormone deficient 
adults.
Author: Dr O.R.Adetunji
Growth hormone (GH) deficiency developing in adult life results in impaired quality of life 
(QoL) and altered body composition (BC). As in children, it is now standard practice to 
treat adult growth hormone deficiency (GHD) with recombinant human GH (rhGH). 
Response to treatment with rhGH remains variable in patients with GHD. In health, the 
growth hormone receptor (GHR) is the principal regulator of growth hormone sensitivity 
and is an obvious candidate gene to influence the response to rhGH. A common 
polymorphism occurs in the GHR gene resulting in two isoforms of the GHR in humans 
generated either by expression or non-expression of exon 3 of the GHR gene. This results 
in 3 genotypes: full-length only with exon 3 expressed on both alleles i.e. homozygous 
GHR/?; short only with non-expression of exon 3 on both alleles i.e. homozygous GHRd3 
and a combination of the 2 isoforms i.e. heterozygous GHR-J3//Z. Population studies have 
documented that this polymorphism occurs in high frequency with the GWK-d3/fl genotype 
in 25-40% of subjects and the GWK-d3/d3 genotype in 7-15%(l-3).
In children, polymorphism of exon 3 of the GHR has been shown to influence response to 
rhGH; children homozygous or heterozygous for exon 3 deletion, d3/d3 or d3/fl show 
better response to treatment, as demonstrated by a superior increase in height velocity.
There are studies in adult GHD populations on the effect of this common polymorphism on 
treatment based on IGF-1 response and other anthropometric measurements (4, 5). To date 
however, there are no studies investigating the effect of this polymorphism on QoL in
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adults with GHD. In this project, we investigated adults with GHD who had been treated 
with rhGH for more than one year in order to determine the relationship between genomic 
deletion of exon 3 in the GHR gene and QoL, body composition (BC) and serum IGF-1 
levels, to determine the effect on this polymorphism on QoL and to compare these 
variables to a healthy adult control population.
The results from the one hundred and seventy-three adult GHD patients studied in this 
project did not support our original hypothesis that patients with the d3/fl or d3/d3 
genotype are less likely to need rhGH therapy to improve quality of life than those with the 
fl/fl genotype.
AIMS OF THE THESIS
Primary:
1. To investigate the frequency of the three exon 3 genotypes in adult patients with GHD
2. To determine whether QoL and BC differ across GHR genotypes in adult patients with 
severe GHD on rhGH replacement therapy.
Secondary:
1. To establish the prevalence of the three exon 3 genotypes in a healthy adult control 
population from the Northwest of England.
2. To investigate relationships between exon 3 genotype, QoL and body composition in 
the control population
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
SECTION 1: THE PITUITARY GLAND - PHYSIOLOGY AND REGULATION OF
THE PITUITARY HORMONES
Anatomy of the pituitary gland
The pituitary gland is a pea-sized organ located at the base of the brain beneath the 
hypothalamus. It is often considered the most important part of the endocrine system 
because it produces hormones that control many functions of other endocrine glands. 
Under-functioning of the pituitary gland, when there is underproduction of one or more of 
its hormones is called hypopituitarism.
The pituitary gland lies within a recess of the median part of the middle cranial fossa in the 
sphenoid bone (sella turcica) and is composed of two major components, the anterior lobe 
(adenohypophysis) and the posterior lobe (neurohypophysis) that can be readily 
distinguished radiologically by magnetic resonance imaging. The anterior lobe contains 
three subdivisions; the pars distalis, pars intermedia and pars tuberalis.
The pars distalis makes up the bulk of the anterior pituitary and is primarily responsible for 
the secretion of anterior pituitary hormones into the peripheral circulation. The pars 
intermedia lies between the pars distalis and the posterior pituitary and is vestigial in 
humans, while the pars tuberalis is well defined in most mammalian species and surrounds 
the infundibular stem. The floor of the sella, or lamina dura, abuts the sphenoid sinus, 
allowing direct surgical access to the pituitary by the transsphenoidal route. Other 
important boundaries to the pituitary gland are the cavernous sinus laterally, which contains 
the internal carotid artery surrounded with sympathetic fibres, and the cranial nerves III, 
IV, V (ophthalmic and maxillary branches), and VI. The optic chiasm is located 
superiorly, separated from the pituitary by the cerebrospinal fluid-filled suprasellar cistern 
and the dural roof of the pituitary, the diaphragma sella.
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Embryologic Anatomy
The posterior lobe of the pituitary gland is smaller than the anterior lobe and 
embryologically derives from the neural primordia as an out-pouching from the floor of the 
third ventricle. Embryologically, the hypothalamus is derived from forebrain tissue and 
lies in the midline on the floor of the third ventricle. It is made up of multiple nuclei 
arranged in four regions (preoptic, supraoptic, tuberal & mammillary regions) and three 
zones: periventricular, medial and lateral zones(6). It is functionally and intimately linked 
to the pituitary gland through the rich portal circulation around the median eminence. The 
hypothalamic neurones synthesize hypophysiotropic releasing and inhibiting hormones directly 
into the portal system which influences the function of the anterior pituitary gland. In contrast, 
neurones from the supra-optic and tuberohypophyseal nuclei directly innervate the posterior 
pituitary gland (7). The pituitary gland lies within the pituitary fossa of the sphenoid bone 
above the sphenoid sinus. Embryologically and functionally the pituitary gland comprises two 
distinct parts. The epithelial portion, which forms the anterior pituitary, has its origin from the 
stomodeal ectoderm of the Rathke’s pouch. The neural portion which forms the posterior lobe, 
pituitary stalk, and infundibulum arises along with the rest of the hypothalamus from the 
diencephalic forebrain (7).
The blood supply to the pituitary is in keeping with this dual origin. The anterior gland 
receives a majority of its blood supply from the hypothalamo-hypophyseal portal system with 
some remaining blood supply via the pituitary capsular vessels derived from the superior 
hypophyseal arteries. The neurohypophysis receives its blood supply from the inferior 
hypophyseal branches of the internal carotid artery. Venous drainage from the anterior 
pituitary is via the cavernous sinuses, principally into the petrosal sinuses and thence into the 
internal jugular veins.
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Physiology of the Pituitary Gland
Microscopically, the anterior pituitary is composed of nests or cords of cuboidal cells 
organized near venous sinusoids lined with a fenestrated epithelium into which secretory 
products from the anterior pituitary are collected. Classically, five cell types and six 
secretory products of the anterior pituitary gland can be identified immunocytochemically 
including the somatotroph (GH), lactotroph (prolactin), corticotroph (adrenocorticotropic 
hormone, ACTH), thyrotroph (thyroid-stimulating hormone, TSH), and gonadotroph 
(luteinizing hormone, LH and follicle-stimulating hormone, FSH) cells. It is now 
recognized, however, that the anterior pituitary is vastly more complicated. In addition to 
morphological and physiological evidence for heterogeneity among the classical anterior 
pituitary cell types and the presence of clusters of a unique cell type, the folliculostellate 
cell, the anterior pituitary can also synthesize numerous other non-classical peptides, 
growth factors, cytokines, binding proteins and neurotransmitters that are important for 
paracrine and/or autocrine control of anterior pituitary secretion and/or cell proliferation 
under defined physiological conditions.
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Figure 1.1: Schematic showing the vascular and hormonal function of the hypothalamus and pituitary 
gland (Source of image: www.medscape.com)
The anterior lobe produces the following hormones, which are regulated by the 
hypothalamus:
• GH - Stimulates growth of bone and tissue (growth hormone deficiency in children 
results in growth failure. Growth hormone deficiency in adults' results in problems 
in regulating body fat and muscle and bone mass resulting in increased body fat and 
reduced muscle and bone mass. It is also involved in emotional well-being.
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• TSH - Stimulates the thyroid gland to produce thyroid hormones. Lack of thyroid 
hormones either because of a defect in the pituitary or the thyroid itself is called 
hypothyroidism.
• ACTH - Stimulates the adrenal gland to produce several related steroid hormones
• LH and FSH - Hormones that control sexual function and production of the sex 
steroids; estrogen and progesterone in females and testosterone in males
• Prolactin - Hormone that stimulates milk production in females
The posterior lobe produces the following hormones, which are not regulated by the 
hypothalamus:
• Antidiuretic hormone (vasopressin) - Controls water loss by the kidneys
• Oxytocin - Contracts the uterus during childbirth and stimulates milk production 
The hormones secreted by the posterior pituitary are actually produced in the brain and 
carried to the pituitary gland through nerves and stored within vesicles in the pituitary 
gland.
Regulation of Pituitary Hormones
Secretion of anterior pituitary hormones is not autonomous. Each hormone is subject to 
regulation by hypothalamic peptides and, with the possible exception of prolactin, subject 
to the fundamental endocrine regulatory mechanism of negative feedback by the hormone 
from the target gland. This negative feedback control is at both the hypothalamic and 
pituitary levels and ensures precise homeostatic maintenance of physiologically appropriate 
hormonal secretion. If the primary gland fails, this results in reduced negative feedback 
and consequently increased hypothalamic and pituitary stimulation and secretion. 
Conversely, primary over-activity of the target gland results in increased negative feedback 
and diminished hypothalamic and/or pituitary stimulation. Pituitary hormones are
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synthesized as part of large precursor molecules and they are then cleaved into fragments 
that are secreted into the circulation. One fragment is the main functional and the other co­
secreted fragments have no known function as endocrine factors.
SECTION 2: GROWTH HORMONE
Growth hormone (GH) is synthesized by the acidophilic somatotroph cells of the anterior 
pituitary gland which make up 35% to 45% of pituitary cells. Human GH is a single chain 
protein with 191 amino acids and two disulfide bonds. The GH gene is located on 
chromosome 17. Approximately 75% is secreted in the 22kD form, while the remainder 
consists of a 20kD variant produced by alternate splicing. GH is secreted by the 
somatotroph cells located primarily in the lateral wings of the anterior pituitary. The 
morphological characteristics and number of these cells are remarkably constant 
throughout life, while secretion changes over time.
55 50
Figure 1.2: Covalent structure of the human growth hormone 
(Source: Chawla RK. et al Ann Rev Med 1983;34:519-547)(8)
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Pulsatile GH secretion in Humans
GH secretion occurs in a pulsatile fashion with a circadian rhythm in normal adults 
characterised by stable low levels interrupted by secretory bursts with a maximal release in 
the second half of the night. These GH-secretory bursts follow from multiple GHRH- 
secretory bursts into the hypophyseal portal circulation. In both children and young adults, 
maximal GH secretion occurs with the onset of the first slow wave sleep (usually within the 
first hour of sleep) (9). In adult men, the GH secretory pulse with the onset of slow wave 
sleep (phase 3 and 4 NREM sleep), is the highest and sometimes the only pulse observed 
throughout the day. In addition to this gender related difference in rhythmicity, the 
cumulative GH secretion in a 24-hour period is also influenced by age, pubertal status and 
nutritional status. Between pulses, GH levels are extremely low and in the majority of 
normal healthy adults, it is below the lower detection limit of assays; making random GH 
measurements unlikely to be of any value (apart from in states of excess GH secretion) 
(10).
In women with normal menstrual cycles, 24-hour GH pulses are higher than age matched 
men, daytime pulses are more frequent and the sleep associated GH pulse is not the major 
contributor of the total GH release (see figure 1.3). In a small group of healthy middle- 
aged men and premenopausal women, highly sensitive immunofluorometric assays 
(sensitivity 0.011 pg/1) and blood sampling at 10-min intervals showed the 24-h GH 
secretion was three times higher in the women, the GH secretory episodes were larger and 
more prolonged, more GH was secreted per burst, and maximal plasma GH concentrations 
were higher than in men (11).
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Figure 1.3: Profile of 24-hour serum GH in human female (top panels) and males (bottom panels) 
subjects (11).
A. REGULATION OF THE GROWTH HORMONE
Biologically active GH (GH1; OMIM 139250) binds its transmembrane receptor (GHR), 
which dimerizes to activate an intracellular signal transduction pathway leading to 
synthesis and secretion of insulin-like growth factor 1 (IGF-1; OMIM 147440). In plasma, 
IGF-1 binds to the soluble IGF-1 receptor (IGF-1 R; OMIM 147370). At target cells, this 
complex activates signal-transduction pathways that result in the mitogenic and anabolic 
responses that lead to growth.
Two hypothalamic hormones regulate GH secretion; Growth Hormone Releasing Hormone 
(GHRH) with a stimulatory action at the level of gene transcription and somatostatin (SST) 
with an inhibitory effect on the GH secretion from the pituitary gland. Various 
synthetically produced GH releasing compounds and the recently discovered natural
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hormone Ghrelin probably have a dual effect in increasing the release of GHRH and 
inhibiting SST action, thereby resulting in a very powerful stimulation of GH secretion. GH 
acts both directly through its own receptor and indirectly through the induced production of 
IGF-1. IGF-1 is synthesized both in the liver and in the periphery, and is an important 
mediator of GH actions. It circulates bound to a number of different binding proteins of 
which IGFBP-3 is the most important.
B. FACTORS CONTROLLING GROWTH HORMONE SECRETION 
Hypothalamic factors
It is thought that the pulsatile release of GH is mediated via the alternating secretions of 
GHRH and SST (12); GHRH is released during the trough of SST secretion.
GHRH, synthesised in the arcuate nucleus and ventromedial nucleus, stimulates both GH 
synthesis and secretion. GHRH exists in two major forms in-vivo; a 40 amino acid and 44 
amino acid form, however, only the first 29 amino acid residues are required to exert full 
biological activity (13). In humans, the gene encoding for GHRH is located on 
chromosome 20 (14). The effect is mediated by the human GFIRH receptor, expressed in 
pituitary cells (15). The GHRH receptor is a 423 amino acid structure and the receptor 
gene has been mapped to chromosome 7 (16). In addition to the hypothalamus, GHRH 
synthesis has also been found at the cerebral cortex, brainstem, testis and placenta 
suggesting that GHRH has a role in the autocrine and paracrine regulation of extra- 
hypothalamic tissues (17).
SST was discovered in the late 1960’s by Krulich et al (18). SST inhibits GH release 
without affecting synthesis (19, 20) and arises from the periventricular and paraventricular 
nuclei. SST exists in two main forms; 14 amino acid and a 28 amino acid peptide, although 
larger forms are known to exist (21). The hypothalamus contains large concentrations of
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SST containing cells, however these cells are also found in the gastro-intestinal tract, 
particularly the secretory cells of the gut and pancreas (22). Five SST receptor subtypes 
have been characterized and the type 5 receptor (sst-5) appears to mediate most of the 
suppression of GH secretion by SST (23). In addition to inhibiting GH release, SST also 
inhibits release of TSH, a range of gastro-intestinal endocrine and exocrine functions and 
antagonises the release of hormones from a variety of endocrine secreting tumours (22).
GH exerts a negative feedback effect on its own secretion. Daily subcutaneous 
administration of exogenous GH for two to five days decreases the endogenous GH 
response to GHRH (24-26). This effect may be mediated by an increase in IGF-1 
concentrations. Recent evidence suggests that GHRH and SST secreting neurons may 
interact with the hypothalamus. In vitro SST inhibits GHRH release (27) and GHRH 
stimulates SST release from perfused rat hypothalami (28). Such intra-hypothalamic 
interactions between these two peptides may contribute to the regulation of pulsatile GH 
release.
Neurotransmitters
A number of central neurotransmitters as well as a variety of peripheral feedback signals, 
regulate GH secretion either by acting directly on the anterior pituitary gland and/or by 
modulating GHRH or SST release, or both, from the hypothalamus (see figure 1.4). 
Pharmacological studies in humans reveal that activation of ai - adrenergic receptors and 
muscarinic cholinergic receptors stimulate GH secretion; antagonists of these receptors 
suppress GH release (29, 30). The influence of a2-adrenergic neurons appears to be 
dominant since co-administration of clonidine (012 - adrenergic agonist) and atropine (a 
muscarinic cholinergic agonist) stimulate GH release. Furthermore, treatment with 
yohimbine (ct2 — adrenergic antagonist) can completely block the stimulatory effects on GH
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secretion of enhancing cholinergic tone with pyridostigmine, a cholinesterase inhibitor
(31).
In contrast, p-adrenergic receptors appear to mediate significant inhibitory effects on GH 
release (see table 1.1). Several studies have demonstrated that blockade of p-adrenergic 
receptors enhances the GH response to GHRH and other provocative stimuli but appear to 
have no effect on spontaneous GH secretion in boys with constitutional delay of growth 
(29, 30, 32). Administration of salbutamol, a p2-adrenergic agonist, inhibits GH secretion 
whereas nicotinic cholinergic and oti-adrenergic receptors appear to have lesser effects on 
GH secretion. Although a-adrenergic and cholinergic neurotransmission are likely to have 
important roles in regulating GH secretion in humans, it is still unknown whether the 
stimulatory effects on GH secretion of these pathways are mediated by suppression of SST 
release or stimulation of GHRH secretion or both.
serofonfn(1-D)
galanin---------
GABA(-B)—> L-arginine
GHRH Somatostatin
Figure 1.4. Principal neurotransmitters regulating GH secretion (30)
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Sex Steroids
The relationship between GH release and sex steroids is complex. Circulating GH 
concentrations in males and females are similar before puberty but increase markedly at the 
onset of puberty (33). This increase in GH secretion during puberty is closely correlated to 
the increase in sex steroids (34, 35).
Although GH levels are three times higher in pre-menopausal women compared to age- 
matched men, the levels of IGF-1 in women are similar to men (11). The variation in GH 
secretion between sexes has been attributed to endogenous oestrogen with oestradiol levels 
being positively correlated with GH concentration and pulse amplitude (36). It is thought 
that the main gender difference is the amount of GH secreted per pulse, with higher pulse 
amplitude in women (11).
In women, the fall in oestradiol that occurs following the menopause is associated with a 
reduction in GH secretion (37, 38). In healthy post-menopausal women, a reduction in IGF- 
1 levels has been documented following oral oestrogen replacement (39). In contrast, when 
post-menopausal women were given transdermal oestrogen replacement, IGF-1 levels 
increased to pre-menopausal levels (39). The disparity between the two different routes of 
oestrogen administration on IGF-1 levels may be due to the first pass metabolism effect of 
oestrogen on the liver resulting in reduced hepatic IGF-1 production(39). The resultant 
decrease in IGF-1 therefore acts via a negative feedback mechanism to increase GH 
production in women. Furthermore, there is evidence to suggest that oestrogen also 
enhances the ability of GHRH to secrete GH (40, 41).
Female patients with growth hormone deficiency (GHD) have lower IGF-1 levels 
compared to men (42, 43) and they also require higher doses of GH to achieve similar 
clinical effects and IGF-1 levels to men (42, 43). Span et al also demonstrated that GHD
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women on oral oestrogen replacement had lower IGF-1 levels compared to eugonadal 
GHD women at the same GH replacement dose (43).
Serum testosterone also stimulates GH secretion and during puberty, serum testosterone 
and GH levels are strongly correlated in boys (44). In a study of boys with 
hypogonadotrophic hypogonadism, testosterone treatment increases the amount of GH 
secretion per GH pulse. It is thought that the action of testosterone on GH secretion is 
mediated by the oestrogen receptors as the effect of testosterone on GH secretion is 
reduced by anti-oestrogens but not anti-androgens (45,46) .
Thyroid Hormones
Studies in rodents have shown that thyroid hormones are able to stimulate GH release (47), 
whilst a reduction in GH secretion and levels were seen in rodents with hypothyroidism; 
this response was corrected with thyroid replacement (48). Thyroidectomy in neonatal rats 
also resulted in a reduction in pituitary GH mRNA levels (49). In humans, transient GHD 
in a patient with long-standing hypothyroidism, which was restored with thyroxine 
replacement, has also been reported(50). In hypothyroidism, IGF-1 and IGFBP-3 levels are 
diminished and this is possibly mediated through GH secretion (51, 52). In humans, 
experimental thyrotoxicosis factitia did not cause any significant change in these 
parameters.
Glucocorticoids
Glucocorticoids have two effects on GH secretion; chronic glucocorticoid exposure 
inhibits, whilst acute glucocorticoid administration enhances GH release and causes a 
transient increase in circulating GH (53). Casanueva et al (53) showed that plasma GH 
concentrations increasedtwo hours after administration of dexamethasone and peaked at
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three hours, then decreased five hours post dose. The exact mode of action of 
glucocorticoids on GH secretion is unknown but the secretion of GH to various stimuli is 
blunted in patients on chronic glucocorticoid treatment and in those with Cushing's 
syndrome (54).
Dexamethasone can also induce a marked increase of serum IGF-1 and a minor increase of 
IGFBP-3 (55). Corresponding changes are found in Cushing's syndrome (56). This can be 
explained by stimulation of gene expression in the liver (57). Cortisol also suppresses the 
IGF-1 expression in osteoblasts (58).
Ghrelin
Ghrelin is a natural ligand of the growth hormone secretagogue receptor (GHS-R) (59) and 
is known to be a potent stimulator of GH release in healthy adults (60). The maximum 
stimulatory effect on GH secretion by ghrelin is ~ 5 fold greater than that achieved by 
GHRH. Ghrelin induced GH release requires an intact hypothalamic-pituitary pathway as 
shown by the proportionately lower GH levels stimulated by ghrelin in vitro compared to in 
vivo and in patients with organic disease of the hypothalamic pituitary region (61).
Although ghrelin stimulates GH secretion directly, a number of studies have demonstrated 
that ghrelin is not essential for GH secretion induced by well-known physiological 
parameters such as exercise, fasting and insulin induced hypoglycaemia (62, 63). Gut 
derived ghrelin, therefore, is not a major regulator of pituitary GH secretion under normal 
conditions.
Other factors influencing GH secretion
Stress, hypoglycaemia and ingestion of protein (high levels of circulating amino acids) 
stimulate GH secretion, while high levels of glucose and free fatty acids (FFA) inhibit 
secretion. With the introduction of reliable radio-immunological assays it was recognized
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that circulating GH was blunted in obese subjects, and that normal aging was accompanied 
by a gradual decline in GH levels. The latter observation led Rudman et al. to the 
hypothesis that many of the senescent changes in body composition and organ function 
were related to or caused by hypo-somatotropinaemia (64) which is termed "somatopause". 
More recent studies have documented that hypopituitary adults with severe GHD are 
characterized by increased fat mass and reduced LBM (65). It is also known that normal 
GH levels can be restored in obese subjects following massive weight loss (66), and that 
GH substitution in GHD adults normalizes body composition (65).
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Table 1.1: Summary of factors that control GH release in humans
Factors Stimulatory Inhibitory
Physiologic Fasting
Exercise
Slow wave sleep
Stress
Post prandial hyperglycaemia
Elevated NEFA
Aging
Hormones Insulin
Sex steroids
Glucocorticoids - Acute
Ghrelin
Thyroid hormones
Glucocorticoids - Chronic
Neuropeptides GH-releasing hormone (GHRH) Somatostatin (SS)
Atropine (muscarinic
cholinergic agonist)
Salbutamol (p2 - agonist)
Clonidine (a2 - adrenergic
agonist)
Yohimbine (a2 - antagonist)
P-adrenergic antagonist Nicotinic cholinergic agonists
Serotonin agonists
Pyridostigmine
Growth hormone secretagogues
Galanin
Hexarelin
Dopamine
Serotonin antagonists
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C: METABOLISM OF GROWTH HORMONE
In health, the growth hormone receptor (GHR) is the principal regulator of sensitivity to 
growth hormone (GH).
Biologically active growth hormone binds its transmembrane receptor, GHR which 
dimerizes to activate an intracellular signal transduction pathway leading to synthesis and 
secretion of IGF-1. In plasma, IGF-1 binds to the soluble IGF-1 receptor. At target cells, 
this complex activates signal-transduction pathways that result in the mitogenic and 
anabolic responses that lead to growth.
Growth hormone receptors have been identified in many tissues including muscle, adipose 
tissue, liver, heart, kidney, brain and pancreas (67, 68) and are part of the cytokine receptor 
superfamily (69). The GHR exists in three forms, the full-length, long form composed of 
620 amino acids, and two short forms of either 277 or 279 amino acids in length (70). One 
of the short forms is membrane-bound, with a much shorter cytoplasmic domain. The 
soluble form of the GHR is also known as the GH-binding protein (GHBP) (71), which is 
identical to the extracellular domain of the GHR.
The initial step in the activation of the GH signal transduction pathway is dimerization of 
the receptor (72). Janus kinase 2 (JAK2) is the receptor-associated kinase inducing 
tyrosine phosphorylation (73). Dimerization brings together the two JAK2 molecules, and 
the activated JAK2 phosphorylates certain tyrosine residues of the cytoplasmic domain of 
the receptor, and other molecules adjacent to the receptor-JAK2 complex. Among these 
are the signal transducers and activators of transcription (STAT) proteins (74). The 
phosphorylated STAT proteins translocate into the nucleus, bind to DNA, and activate the 
transcription of specific genes. The administration of GH in vivo to hypophysectomized 
rats induces stimulation of STAT 1, -3, -5 in liver nuclear fraction (75-77), whereas this 
effect has been shown in non-hypophysectomized rats for JAK2 and STAT 5 (78). GH
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activates STAT 5 proteins in adipocytes (79) and a mutation in the gene for STAT 5b 
results in IGF-1 deficiency and GH insensitivity with profound growth failure (80). The 
JAK/STAT pathway is, in turn, negatively regulated by several proteins, including 
suppressor of cytokine signalling (SOCS) 1-7 (70). Analysis of STATSb deficient mice 
shows that they have a gender related deficiency in body growth, which is seen in males 
but not females. They also had elevated plasma GH levels and reduced IGF-1 as well as 
reduced GH induced lipolysis in adipose tissue. In adipocytes, fibroblasts and Chinese 
hamster ovary cells the insulin-responsive docking proteins, insulin receptor substrate 
(IRS)-l and -2, are rapidly phosphorylated in response to GH, and phosphorylated tyrosine 
residues in these docking proteins provide binding sites for phosphatidyl-inositol-3'-kinase 
(Pl-3-kinase)(81). GH also affects adaptor proteins leading to the activation of the 
Ras/mitogen-activated protein (MAP) kinase (82) which might involve cross-talk with the 
activated epidermal growth factor (EGF) receptor (83). Protein kinase C also appears to 
play a role in GH signalling, as treatment with inhibitors of protein kinase C decreases GH 
induction (70).
GH signal transduction pathways
Figure 1.5: GH signal transduction pathway
[Source: Adapted from N Eng J Med, 2003 349( 12)](84)
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Insensitivity to Growth Hormone
Animal studies and human mutational analysis have both supported a central role for the 
IGF system in postnatal growth. Responsiveness to GH in target cells is primarily 
dependent upon the expression of the GH receptor.(84)
In the normal GH-IGF axis, there are potential biochemical defects capable of causing 
insensitivity to GH: abnormalities of the GHR or of the binding protein or both and 
abnormal signal transduction. Genetic mutations leading to biochemical defects in this axis 
usually present in children as short stature and often result in complex syndromes. 
Heterogeneous mutations which may result in normal growth but later impact on response 
to therapy with rhGH are largely unexplored with the exception of exon 3 which encodes 
the extracellular domain of the GHR gene.
D. FUNCTIONS OF GROWTH HORMONE
A critical concept in understanding growth hormone activity is that it has two distinct types 
of effects:
• Direct effects are the result of growth hormone binding its receptor on target cells. 
Adipocytes, for example, have growth hormone receptors, and growth hormone 
stimulates them to break down triglyceride and suppresses their ability to take up 
and accumulate circulating lipids.
• Indirect effects are mediated primarily by IGF-1, a hormone that is secreted from 
the liver and other tissues in response to growth hormone. The majority of the 
growth promoting effects of growth hormone is actually due to IGF-1 acting on its 
target cells.
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Growth Hormone on Growth
Growth is a very complex process, and requires the coordinated action of several 
hormones. The major role of GH in stimulating body growth is to stimulate the liver and 
other tissues to secrete IGF-1. IGF-1 stimulates proliferation of chondrocytes (cartilage 
cells), resulting in bone growth. Growth hormone also seems to have a direct effect on bone 
growth in stimulating differentiation of chondrocytes(85).
IGF-1 also appears to be the key player in muscle growth. It stimulates both the 
differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and 
protein synthesis in muscle and other tissues.
Metabolic functions of Growth Hormone
Growth hormone has important effects on protein, lipid and carbohydrate metabolism. In 
some cases, a direct effect of GH has been clearly demonstrated, in others, IGF-1 is thought 
to be the critical mediator and in some cases it appears that both direct and indirect effects 
are at play.
• Protein metabolism: In general, GH stimulates protein anabolism in many tissues. 
This effect reflects increased amino acid uptake, increased protein synthesis and 
decreased oxidation of proteins.
• Fat metabolism: Growth hormone enhances the utilization of fat by stimulating 
triglyceride breakdown and oxidation in adipocytes.
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• Carbohydrate metabolism: Growth hormone is one of a battery of hormones that 
serves to maintain blood glucose within a normal range. Growth hormone is often 
said to have anti-insulin activity, because it suppresses the abilities of insulin to 
stimulate uptake of glucose in peripheral tissues and enhance glucose synthesis in 
the liver. Somewhat paradoxically, administration of GH stimulates insulin 
secretion, leading to hyperinsulinemia.
SECTION 3: GROWTH HORMONE DEFICIENCY
Two main categories for GHD are childhood onset GHD (COGHD) which maybe 
congenital or acquired and adult onset GHD (AOGHD) which may have been developed 
childhood or be acquired in adult life.
A: Childhood Onset GHD
Idiopathic GHD is the most common cause of GHD in children(86). It is a poorly defined 
and often reversible condition that presents with short stature and low growth velocity for 
age with a prevalence of 1 in 3500 children. Most cases of COGHD are idiopathic (87) and 
are not necessarily associated with other pituitary hormone deficiencies (Table 1.2). 
Various genetic factors have been found to be responsible for idiopathic GHD.
GHD in childhood is also associated with congenital anomalies and malformations and 
there are many acquired causes (Table 1.2). There are several forms of congenital GHD, 
which are subdivided into idiopathic, genetically determined and structural lesions of the 
hypothalamic-pituitary area. There have been several large studies examining the aetiology 
of GHD in children. A previous survey of 325 children with GHD showed that 21.9% had 
organic lesions, 69.5% were idiopathic and 8.6% had hereditary forms of GHD (88). A 
later survey in England and Wales in 1977 also showed similar results in children with 
GHD, with organic lesions accounting for a quarter to a third of cases, 3% were hereditary
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and the remainder were idiopathic in nature (21). In children with idiopathic congenital 
GHD, the main abnormality is thought to lie in the hypothalamus, as the majority of these 
children are able to produce GH in response to GHRH or one of the GH releasing 
analogues (89).
It is thought that far more cases of GHD have a genetic aetiology than are currently 
recognised (88). GHD is often not absolute; there is a wide range of GH secretory capacity; 
from the mild to the severe end of the spectrum (90). Different genetic forms of GHD have 
been identified; some causing isolated GHD and others are associated with other pituitary 
hormone deficiencies.
Idiopathic GHD has been associated with birth trauma as a higher incidence of birth trauma 
(65%) is seen in those with hypopituitary dwarfism when compared to the normal 
population (3-4%) (88). Non-cephalic deliveries were also more commonly seen in patients 
with so-called ‘idiopathic’ GHD with higher incidences of breech and forceps deliveries in 
those with multiple hormone deficiencies compared with those with isolated GHD(21). The 
association with non-cephalic deliveries may be due to the high number of brain injuries 
resulting from such procedures, but it is also thought that idiopathic GHD may be a multi­
factorial disorder(21). With improvements in obstetric practice, such lesions are now less 
common.
Vaginal bleeding occurring during the first two trimesters of pregnancy may also be 
another risk factor; 7.1% of pregnancies resulting in GHD were associated with vaginal 
bleeding compared with 3% in the normal population^ 1).
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Table 1.2: Causes of Childhood Onset GHD
1. Congenital Conditions
a. Anatomical anomalies
i. Stalk dysgenesis, with or without ectopic posterior pituitary
ii. Encephalocoele
iii. Empty sella
b. Genetic factors
i. Mutations in the Pit-1 gene
ii. Mutations in the PROP-1 gene
iii. Mutations in the GHRH-receptor gene
iv. Fanconi’s syndrome
v. Septo-optic dysplasia
vi. Panhypopituitarism
c. Idiopathic (usually due to GHRH deficiency)
2. Acquired Conditions
a. CNS Tumours
i. Hypothalamic
ii. Pineal
iii. Pituitary tumours
iv. Craniopharyngiomas
v. Rathke’s cleft cysts
b. Cranial Irradiation
i. Administered for tumours or infiltrative diseases
c. Infiltrative Diseases
i. Langerhans’ cell histiocytosis
ii. Sarcoidosis
iii. Tuberculosis
iv. Lymphocytic hypophysitis
v. Haemochromatosis
d. Trauma
e. Hypoxic Insult
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B: Adult Onset GHD
In contrast to COGHD, adult onset GHD generally presents as part of a combined pituitary 
hormone deficiency phenotype (hypopituitarism) and is commonly attributable to a 
pituitary tumour or other structural lesions of the hypothalamic-pituitary axis (91, 92) 
and/or treatment with surgery or radiotherapy(93).
AOGHD commonly results from intra-cranial tumours, either as a direct consequence of 
the tumour or its treatment particularly after radiotherapy (94). The majority of these 
tumours are benign with pituitary adenomas being the main cause of hypopituitarism, hi a 
study of 333 adult patients with hypopituitarism, pituitary adenoma was identified in 223 
patients (91). Intra-cranial developmental tumours such as astrocytomas, medulloblastomas 
and craniopharyngiomas are much less common. These are developmental tumours and 
usually occur above the sella (88). Inflammatory granulomatous conditions affecting the 
pituitary may also lead to GHD (Table 1.3).
In another study of 165 patients with pituitary tumours when evaluated before surgery, 50 
% already had evidence of GHD (95). After surgery about 80 % had evidence of GHD and 
it developed in all those who had post-operative radiotherapy. The incidence of AOGHD is 
not known, but indirect estimates based on the incidence of pituitary tumours suggest an 
incidence of 10 people/million annually (96) with a prevalence of probably about 1 per 
10,000 in the European population (97).
In the development of hypopituitarism due pituitary tumours, loss of the hormones follows 
a characteristic sequence. GH secretion is the first one to be impaired followed by LH and 
FSH and finally TSH and ACTH.
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Table 1.3: Causes of Adult Onset GHD
Pituitary Adenoma 
Rathke’s cysts
Cranial irradiation
Post-hypothalamo-pituitary
surgery
Post pituitary radiotherapy 
Para-sellar meningiomas
Suprasellar germ cell tumours 
Post-partum pituitary necrosis 
Rathke’s cysts
Craniopharyngioma
Metastatic disease in the pituitary
gland
Sub-Arachnoid Haemorrhage 
Lymphocytic hypophysitis
Langerhans’ cell histiocytosis 
Granulomatous infiltrations 
Sarcoidosis, Haemochromatosis 
Idiopathic
Traumatic Brain Injury
Metastatic disease in the pituitary
gland
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GHD associated with pituitary tumours
Macroadenomas (pituitary tumours greater than 1 cm) are associated with one or more 
trophic hormone deficit in about 30% of cases(98) with direct compression and destruction 
of the surrounding normal pituitary leading to hormone hyposecretion. Other postulated 
mechanisms include primary mass effect of the tumour on the vascular portal 
system/pituitary stalk, raised intrasellar pressure affecting portal circulation, and focal 
pituitary necrosis secondary to prolonged interruption of portal blood supply(99, 100). 
While microadenomas (< 1 cm) rarely affect pituitary function(lOO), prolactin producing 
microadenomas often present with hypogonadism because of the suppressive action of a 
high prolactin (PRL) level on secretion of gonadotrophins (follicle stimulating hormone 
FSH and luteinising hormone LH). Among the peri-pituitary tumours causing central 
endocrine dysfunction, craniopharyngioma is the commonest, Craniopharyngioma is the 
most common tumour in the hypothalamo-pituitary region to cause pituitary deficiency in 
childhood. The tumour usually arises from remnants of Rathke's pouch, an invagination of 
the epithelium within the third pharyngeal pouch from which the anterior pituitary evolves. 
Although histologically a benign tumour, craniopharyngiomas can be locally invasive, 
involving adjacent structures especially the optic tracts and base of the third ventricle. It 
usually has a solid and cystic component that may contain a cholesterol-rich fluid. GH 
deficiency (72%) is the most common endocrine abnormality at clinical presentation, 
followed by short-stature in 53% whereas ACTH, TSH and ADH deficiencies were found 
in approximately 25% of cases. Meningiomas disrupt the neuro-anatomic connections and 
vascular supply of the hypothalamic-pituitary axis to result in hypopituitarism either 
directly tfom mass effects or as a result of treatment(s) (101).
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GHD following Surgery
Hypopituitarism can be a consequence of pituitary surgery. The incidence and degree of 
hypopituitarism depend on several factors, including the size of the original tumour, the 
degree of infiltration, and the experience of the surgeon. Following surgery endocrine 
deficiencies of ACTH, TSH, GH, LH, FSH and ADH are highly likely, therefore these 
patients should be carefully monitored and appropriate hormonal replacement therapies 
commenced promptly.
Surgery for pituitary adenomas may also be followed by significant recovery of pituitary 
function; up to 50% of patients recover at least one pituitary hormone that had been 
deficient before trans-sphenoidal surgery (99, 102, 103). Postoperative improvement is 
more likely if there is no tumour on postoperative imaging and no neurosurgical or 
pathological evidence of an invasive tumour (102). GH is less likely to recover than 
gonadotrophins, ACTH and TSH (99). There is evidence that among those patients in 
whom recovery of pituitary function occurs, the process begins immediately after surgery 
(103).
GHD following radiotherapy
Growth hormone deficiency (GHD) is the most frequent complication and usually the only 
overt manifestation of neuroendocrine injury in the vast majority of irradiated patients 
including non-pituitary brain tumours.(104) Radiation-induced damage of the 
hypothalamo-pituitary axis (HPA) is believed to be neuronal rather than vascular(105). The 
hypothalamus is a highly radiosensitive structure and is thought to be the primary site of 
radiation damage, particularly with radiation doses of more than 50 Gy. The severity and 
speed of onset of radiation-induced GH deficiency is dose-dependent. Hypothalamic- 
pituitary dysfunction secondary to radiation is also time-dependent, with both increased
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incidence and severity of hormonal deficits occurring with longer post-irradiation follow­
up intervals (106-108). The progressive nature of the hormonal deficits following radiation 
damage to the HPA can be attributed to secondary pituitary atrophy consequent upon lack 
of hypothalamic releasing/trophic factors (109, 110) or delayed direct effects of 
radiotherapy on the pituitary.
GHD following Brain Injury and Subarachnoid Haemorrhage
Recent reports suggest hypopituitarism can follow traumatic brain injury (TBI) and sub­
arachnoid haemorrhage (SAH) (101). It is estimated that the prevalence of anterior pituitary 
dysfunction following TBI might be as much as 30-70% (111) with a review by Schneider 
et al in 2007 showing up to 47% after SAH(112). Controversy exists as to the prevalence of 
hypopituitarism following SAH(113, 114) with a number of endocrine societies 
recommending that all patients should undergo evaluation of anterior pituitary function 
after SAH(115, 116).
Patients with an initial Glasgow Coma Scale of < 13 should be evaluated for pituitary 
dysfunction although there is as yet no consensus for the earliest time when this evaluation 
should be carried out. GH is the first hormone to be deficient in 9-40% of patients 
following TBI (117). The natural course of changes in pituitary function in such patients is 
unclear. A prospective review of SAH survivors in the same Walton Centre for Neurology 
and Neuroscience as this study showed a prevalence of of hypopituitarism of 12% after 12 
months follow-up with no predictive factors for the development of hypopituitarism(l 18). 
In the study, Gardner et al recommended the screening for the presence of hypopituitarism 
at least 12 months after the SAH, when potentially reversible pituitary dysfunction has 
resolved.
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Early post traumatic pan hypopituitarism however generally persists as a permanent feature 
and will require appropriate hormone replacement therapy (111).
C: DIAGNOSIS OF GROWTH HORMONE DEFICIENCY
Diagnosis of Childhood Onset GHD
The diagnosis of anterior pituitary GH deficiency in children is difficult due to the pulsatile 
nature of GH secretion. Various tests are available to test GH reserve and can be divided 
into provocation tests and those measuring spontaneous GH secretion. As a normal child 
may fail a single provocative test, it is recommended that two abnormal provocative tests 
are required to diagnose GHD (119). In order to distinguish between genuine GHD and 
constitutional delay in growth and puberty, oestrogen or androgen should be administered 
for a few days before a GH provocative test (120-122).
COGHD requires reconfirmation in adulthood as 35% of idiopathic COGHD patients 
showed normal GH secretory responses when retested as adults (123). This may be related 
to maturation of the hypothalamic-somatotroph axis.
Diagnosis of Adult Onset GHD
In the last two decades, with the increased recognition of GHD as a distinct clinical entity 
in adults and the greater availability of growth hormone replacement therapy, it has become 
increasingly important to accurately diagnose adults with symptomatic GH deficiency. 
Adult GHD (AGHD) is a syndrome consisting of a cluster of clinical features such as 
truncal obesity (124), reduced muscle strength and increased fatigability (125) and 
decreased psychological well-being which has been demonstrated by Wallymahmed et al in 
similar patient population in the North West of England (126). Although these clinical 
features are vague and non-discriminatory, GHD may be suspected if there is also a history 
of pituitary tumour, surgery or radiotherapy.
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The diagnosis of severe GHD is straightforward biochemically within the appropriate 
clinical context. In patients with hypothalamic-pituitary disease, the syndrome of adult 
GHD characteristically manifests with derangements in body composition, physical, and 
psychological function (116). Partial GHD is at present not a well-defined clinical entity in 
adults but the presence of a low 1GF-1 concentration increases the likelihood of GHD, 
Inconclusive testing should be followed by ongoing clinical evaluation and repeat testing. 
The 2007 Consensus guidelines for the diagnosis and treatment of adults with GH 
deficiency II (116) state that patients who should be tested for GHD are those who show 
evidence of hypothalamic-pituitary disease, and in whom there is an intention to treat. This 
includes patients from the following three groups:
(1) Those with signs and symptoms of hypothalamic-pituitary disease (endocrine, 
structural, and/or genetic causes)
(2) Those who have received cranial irradiation or tumour treatment and
(3) Those with traumatic brain injury (TBI) or subarachnoid haemorrhage (116).
One stimulation test is sufficient for the diagnosis of adult GHD. Not all patients suspected 
of having GHD however, require a GH stimulation test for diagnosis. Patients with three or 
more pituitary hormone deficiencies and an IGF-I level below the reference range have a 
>97% chance of being GHD, and therefore do not need a GH stimulation test.
D: GROWTH HORMONE STIMULATION TESTS 
Insulin tolerance test
The insulin tolerance test (ITT) is the accepted ‘gold standard’ for diagnosing GHD(127). 
The ITT is not without problems and should only be used in experienced units and is 
contraindicated in patients with cardiovascular, cerebrovascular disease, epilepsy, severe
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untreated hypoadrenalism and the elderly (127-129). However, in experienced endocrine 
units, the ITT has been reported to be safe (130).
Intravenous insulin is administered to reduce plasma glucose to below 2.2mmol/I and blood 
samples taken every 30 minutes for 2 hours to measure GH and cortisol. The peak 
concentration of GH usually occurs 30-60 minutes after symptomatic hypoglycaemia 
occurs. Using the ITT, the cut-off for severe GHD is a peak concentration of < 3|ag/L 
(9mU/L) (127).
The ITT should be considered only in the appropriate clinical context, i.e., in patients with 
evidence of hypothalamic disease, following pituitary surgery or irradiation and in those 
with childhood onset GHD(127). Furthermore these patients are likely to have multiple 
pituitary hormonal deficits and the probability of GHD increases with increasing numbers 
of pituitary hormonal deficiencies (92). Patients undergoing the ITT should be receiving 
stable and adequate doses of other hormone replacement therapy(127).
Glucagon Stimulation Test
The advantage of the glucagon stimulation test (GST) is that, like the ITT, it is able to 
assess both cortisol and GH secretion(129, 130), also there is good correlation between the 
ITT and GST in releasing cortisol and GH (131-133). With regards to GH release, the GST 
has also been shown to be more effective than arginine(132). The GST is thought to have 
similar specificity and sensitivity to the ITT at the 9mU/L (3 ug/L) cut-off (132, 134). 
Furthermore a later study comparing the different GH secretogoues showed that the mean 
peak GH response was similar between the GST and ITT and that the GST was better than 
the clonidine, pyridostigmine and galanin tests (135). The GST has been shown to be 
second only in terms of efficacy to the ITT in the stimulation of GH and ACTH release 
(128, 132) and can therefore be considered as a suitable alternative when the ITT is 
contraindicated. Unlike the ITT there are few contra-indications to the use of GST.
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The mechanism of glucagon induced GH release is unclear. However, several studies have 
suggested a relationship between the falling blood glucose levels later in the test and peak 
GH levels (136-138). It is likely that other mechanisms other than falling blood glucose 
levels are involved as the hyperglycaemia found in diabetic patients does not seem to 
impair the glucagon induced GH release (131, 139).
Another possible mechanism for glucagon induced GH release is via noradrenaline 
secretion. Glucagon has been shown to induce noradrenaline release in healthy volunteers 
(140). Two peaks of noradrenaline release have been identified; 30 minutes and 
150 minutes post glucagon administration. It was also demonstrated that the timing of side- 
effects corresponded to the second noradrenaline peak and peaks in GH and cortical (140). 
However, there was no correlation between the severity of the side-effects and hormonal 
levels reached. The increase in plasma noradrenaline may be responsible for stimulating 
GH release possibly via a-receptors as administration of a p-blocker enhances GH secretion 
(133, 137, 141).
Intravenous glucagon causes less GH release compared to both intramuscular and 
subcutaneous glucagon (142, 143) and the intramuscular route has been suggested as being 
more reliable and effective at releasing GH(144).
The peak GH levels obtained with the ITT and GST have been shown to be similar in both 
patients and healthy subjects(135, 138) and there is good correlation between the two tests 
(r = 0-645) in peak GH levels obtained (131). Two studies comparing the GST and ITT in 
healthy subjects have shown the GST to be as potent as the ITT in releasing GH in healthy 
individuals (135, 145). Another study showed that when propanolol is taken 2h before 
glucagon administration greater GH release is obtained with the GST compared to the 
ITT(133).
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Contra-indications to the GST include presence of an underlying insulinoma and 
phaeochromocytoma (146). An audit of over 500 consecutive GSTs in patients with 
hypothalamic-pituitary disease showed that the main side effects were nausea, sweating or 
headache, occurring during 20 % of the tests (147). The glucagon stimulation test has 
proved to be a safe, low-cost and effective means of stimulating GH secretion; it does not 
require the constant supervision of an experienced doctor and therefore can be considered 
as a suitable alternative to the ITT.
Other stimulation tests
Many tests have been described to assess GH secretion. Newer tests such as the arginine 
and growth hormone releasing hormone (GHRH) and pyridostigmine and GHRH tests have 
been used as alternatives for the diagnosis of GHD (148, 149). The arginine (which inhibits 
somatostatin release) and GHRH test is considered to be a suitable alternative to the ITT, 
and its ability to stimulate GH release is unaffected by the age of the subject(148). The 
pyridostigmine and GHRH test has been shown only to be reliable for those between the 
ages of 20-40 years (148). However, a later study comparing the pyridostigmine and 
GHRH test to the ITT showed the pyridostigmine and GHRH test to be a more potent GH 
secretogogue than the ITT (149). In addition to the new tests, the arginine and glucagon 
tests can be used as alternatives to the ITT for patients with contra-indications to the ITT 
[Growth Hormone Research Society 1998] (127). Other agents used as secretagogues have 
included L-dopa, nocturnal sleep, clonidine, hexarelin (150) and exercise (151).
Overall, recent evidence from Toogood et al in 2012 shows that the ITT, AST, and GST 
produce similar GH peaks, are influenced by similar clinical factors, and identify patients 
with similar features of GH deficiency at a diagnostic threshold of 3 pg/L (152).
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Measurement of spontaneous GH secretion
GH secretion is episodic in nature and therefore a single GH measurement is of limited 
value in diagnosing GHD. Plasma GH is measured by RIA (polyclonal or monoclonal) or 
by IRMA (immunoradiometric -dual monoclonal). The measured GH concentration 
therefore depends on the type of assay used in its detection. This is because endogenously 
secreted GH has different isoforms (22- and 20-kd monomers, acetylated 22K) with 
different antibodies binding to a heterogeneous spectrum of GH isoforms. Also, the 
secretion of these differing isoforms has an inter-individual variability, making it difficult 
to compare GH results from different immunoassays(153). 24 hour repeated serum GH 
measurements have been used but these are time-consuming; require hospital admission 
and the results are disappointing. There is considerable overlap between GHD patients and 
healthy subjects, so it is not a reliable test (124). Urinary GH measurement in conjunction 
with insulin-like growth factor-1 has been advocated but is unreliable due to GH 
concentrations varying significantly between individuals and within individuals from day 
to day (154).
E: CLINICAL FEATURES OF GROWTH HORMONE DEFICIENCY
Whilst diagnosis of GH deficiency in children is straightforward in its presentation with 
growth retardation, diagnosis of adult onset GH deficiency is much more challenging; 
however, in the presence of a probable cause and other hormonal deficiencies, GHD can be 
attributed as causative of such symptoms.
There is no single symptom or sign that is pathognomonic of GH deficiency in adult life, 
but a well-defined constellation of symptoms and signs has been identified in adults with 
GH deficiency, leading to the recognition of a "growth hormone deficiency syndrome". In
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adult life, GH deficiency is associated with altered body composition, altered metabolism, 
reduced exercise capacity, and impaired quality of life (93, 155).
Effect of GHD on Quality of Life
One of the best recognised clinical aspects of adult growth hormone deficiency (AGHD) 
syndrome in hypopituitary adults is reduced psychological well-being. Hypopituitary 
patients with GHD describe a number of adverse features such as reduced vitality and 
energy, greater emotional lability, social isolation, low mood and an overall poor life 
quality (156, 157). Initial objective measurements of QoL were done using generic health 
status questionnaires such as Nottingham Health Profile (NHP) and Psychological General 
Well Being Schedule (PGWB) (156, 157), but more recently “disease-specific” 
questionnaires have been more widely used (158). The Assessment of Growth Hormone 
Deficiency in Adults questionnaire (QoL-AGHDA/AGHDA) (159) is well validated and 
normative data is available for UK, Spanish and Swedish populations. The AGHDA 
questionnaire has been criticised for the lack of normative reference data in different 
countries; for its inability to take into account differing QoL expectations in different 
countries and by its inability to separate the measured QoL into domains. Another 
questionnaire for use in AGHD is the newer QLS-H (Quality of Life Satisfaction- 
Hypopituitarism) questionnaire, which has the advantage of providing scores which are 
first weighted by each individual patient according to the importance they place on a 
particular item. The National Instititute for Health and Clinical Excellence (NICE) 
recommend treatment for AGHD based on an impaired QoL-AGHDA questionnaire score 
and it is used for the purpose of this study. The QLS-H questionnaire has also been 
validated and widely translated (160, 161). The impairment in life quality reported by 
adults with GHD is heterogeneous in that even with severe biochemical GHD, some adults
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report a normal QoL compared to others with less severe GH deficiency(162). Also, adults 
with COGHD have less significant impairments in life quality in comparison to those with 
who develop GH deficiency in adulthood. The explanation suggested for this difference is 
probably due to an adaptation mechanism whereby those with COGHD have adapted to 
less demanding challenges in life which they can cope with and which is within their 
limitations (162, 163). Li Yoon Chong et al. (164) demonstrated that when one considers 
the effect of normal aging process with QoL in patients with organic hypothalamic pituitary 
disease, elderly patients (mean age 71 years) with GHD were shown to have significant 
impairments in multiple aspects of QoL (e.g. emotional reaction, social isolation, mental 
fatigue) compared to matched controls. Interestingly, Li Yoon Chong et al and 
Wallymahmed et al studying GHD adults in the same endocrine service as those studied in 
this research project showed the overall scores for QoL impairments in the elderly were 
less severe when compared to younger GHD adults (164, 165). Also when the same cohort 
with untreated GHD was followed up over a further 2 years, there were continued 
impairments in some QoL domains (e.g. less energy, less vitality, lower self-esteem) over 
the period of follow up. Additionally, the control group also had similar impairments in life 
quality to a degree which was indistinguishable from GHD patients at the end of 2 years 
(166).
The mechanism(s) underlying the impairment in life quality in GHD adults is possibly 
multifactorial and seems to bear no correlation to metabolic, body composition or 
biochemical parameters. Adults with hypothalamic-pituitary disease require life-long 
hormone replacement treatment(s) and follow-up. It is therefore conceivable that the 
combination of having a chronic illness requiring long term care, the effect of having had 
neurosurgery and/or radiotherapy and the prospect of possibly requiring these in future and 
the effects of treatments on vision, neurological and psychological function may all put
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together contribute to the development of significant impairments of QoL in adults with 
hypopituitarism and GHD (161, 165, 167).
Effects of GHD on body composition
The most conspicuous feature of adult GH deficiency is an abnormal body composition 
characterized by increased fat mass and reduced lean body mass (LBM) (164, 168-171). 
Body fat accumulates preferentially in the visceral and upper body subcutaneous 
compartment and may cause adverse metabolic effects such as impaired insulin sensitivity 
(172, 173). In addition, these patients have reduced bone mass compared with matched 
healthy controls, and are at increased risk of sustaining osteoporotic fractures(174).
The body composition of young and middle-aged adults who develop GHD after puberty 
differs from healthy age matched controls with an increase in total body fat mass and 
central obesity (126, 169, 175-179). Evidence for a central fat distribution comes from 
assessment of waist to hip ratio, skin fold thickness, anthropometric measurements, 
bioelectric impedence (180) and computerised tomography studies (176, 180). It seems that 
the lack of GH causes the redistribution of fat from peripheral to central depots. Patients 
with GHD tend to be heavier, have lower lean body mass and total body water (181).
GH replacement has been shown to correct the abnormal fat distribution in patients with 
GHD. GH replacement in adults with GHD has been shown to normalise body composition 
by leading to an increase in lean body mass and a decrease in fat mass (158, 175-177, 182- 
186). This change in lean body mass (LBM) and fat mass occurs in both COGHD and 
AOGHD (162) and is maintained for at least 7-10 years (187, 188). It is also known that 
normal GH levels can be restored in obese subjects following massive weight loss(66). 
AGHD and hypopituitarism have also been associated with a number of risk factors for 
cardiovascular disease, including vascular endothelial dysfunction, dyslipidaemia, and 
insulin resistance(189). Reduced left ventricular mass, impaired cardiac systolic function.
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and impaired response to peak exercise have also been reported(190). These findings, along 
with the reduced lean body mass, result in reduced muscle strength and exercise capacity.
It is possible that altered body composition may be the single most important factor in 
reducing vascular risk; it has been estimated using the Framingham model that the GH- 
induced difference in WHR could represent a 3-4 % decrease in the incidence of coronary 
heart disease over 10 years (188, 191, 192). However, it should be stressed that this is a 
theoretical projection and it is not clear whether these data apply to GH-deficient patients.
F: GROWTH HORMONE REPLACEMENT THERAPY 
Response and Variability to Growth Hormone Replacement therapy
Variable response has been recorded in children with short stature treated with growth 
hormone. Response varies regardless of the aetiology of GHD: idiopathic, Turner’s 
syndrome, intrauterine growth retardation, or small for gestational age infants.
The effect of GH replacement on body composition has been extensively studied (171, 
193) and beneficial effects have been almost universally observed. Adults with GHD 
demonstrate highly heterogeneous biochemical and clinical responses to treatment with 
rhGH. Wallymahmed et al (126) reported improvement in self-esteem scores following GH 
replacement therapy along with significant improvements in body composition in GHD 
patients while Deepak et al reported significant improvement in peripheral inflammatory 
and cardiovascular risk markers in the same North West England patient population (194). 
Some patients seem to have little improvement in quality of life and body composition 
from GH therapy despite increases in the serum IGF-1 into the normal range, while other 
patients with untreated severe GHD are asymptomatic.
It is possible that these different clinical responses to GH in adults with GHD reflect a 
spectrum of GH sensitivity.
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Effect of GH replacement on Quality of Life
The psychological well-being and QoL of GH-deficient patients and the effects of GH 
replacement have received considerable attention in recent years.
Quality of life is usually accessed via self-administered questionnaires that reflect a variety 
of health-related, economic, and social factors. Quality of life measures may be broadly 
correlated with, but are different from, assessments of affect or cognition. Quality of life 
evaluations of GHD patients have shown a high degree of variability. For example, in the 
untreated state, some patients reported severe impairment in quality of life while others 
reported their quality of life as normal (195). In particular, significant impairment in 
quality of life was less frequently observed in adults with childhood-onset GHD (162). The 
area of quality of life most likely to be affected by GHD was energy and vitality (163) . 
Disease-specific quality of life assessment questionnaires have been validated and are now 
widely used (159, 196). In most studies, self-perceived well-being and QoL have been 
assessed using these validated questionnaires, and comparisons have been made with 
controls of matched age, sex, and socio-economic status (197).
Decreased psychological well-being has been reported in hypopituitary adults who have 
had replacement of all hormone deficiencies with the exception of GH (198). Comparison 
was made between the psychological well-being in 86 adults with GH deficiency and 86 
age-matched controls using the Nottingham Health Profile (NHP) (199); the GH-deficient 
patients reported less energy, greater emotional lability, more difficulties with sexual 
relationships, and a greater sense of social isolation than the control subjects. Stabler et 
n/.(198) evaluated psychosocial adjustment in adults with GH deficiency and in age-, sex-, 
socio-economic and height-matched controls. Those with multiple pituitary hormone 
deficiencies showed less openness and less assertiveness compared with controls.
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A double blind, placebo-controlled study by McCauley et al was the first to demonstrate 
that rhGH (0.5 lU/kg/week; 12.5 pg/kg/day) was associated with an improvement in mood 
and energy levels in GHD adults (163). In the study, all three instruments used, the NHP (to 
assess general health and well-being), the Psychological and General Well-Being Schedule 
(PGWB), and the General Health Questionnaire, showed significant improvements in 
subjective well-being and QoL after 6 months of rhGH. The study was performed without 
knowledge or expectation of the psychological effects of GH therapy, issues that may be 
relevant in the interpretation of subsequent studies.
Whitehead et a/.(200) examined the effects of rhGH (0.25 lU/kg/week; 12.5 pg/kg/day) on 
well-being of 14 adults with GH deficiency in a 6-month, double blind, placebo-controlled, 
cross-over trial using the NHP and the PGWB questionnaires. No significant changes in 
psychological well-being were observed, but many patients failed to demonstrate a 
significant increase in IGF-1, indicating that noncompliance with GH may have accounted 
for these findings. Two QoL-rating scales [Comprehensive Psychological Rating Scale 
(CPRS) and Symptom Checklist-90], examined the effects of 6-month GH replacement 
(0.25 lU/kg/week; 12.5 pg/kg/day) in 26 adults with GH deficiency in a double-blind, 
placebo-controlled, cross-over study (201). GH treatment was associated with a significant 
improvement in the CPRS, but not in the Symptom Checklist-90. The CPRS and General 
Health Questionnaire-90, were used to examine the effects of GH replacement (0.18-0.35 
IU/kg*/eek; 9—17.5 pg/kg/day) on 40 adults in a randomized controlled trial (202). The 
initial 6 months were randomized, but thereafter, patients continuing on GH replacement 
were followed for 18 months. Those initially randomized to placebo reported greater 
morbidity at baseline, and placebo was associated with a significant improvement in CPRS 
compared with GH after 6 months of therapy. Compared to the baseline score, patients
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receiving GH reported an improved CPRS score after 6 and 12, but not 18, months of 
therapy.
Burman et al (156) examined psychological capacity and sense of well-being using the 
Hopkins Symptoms Check List (HSCL), the NHP, and the PGWB in 36 adults with GH 
deficiency and 36 matched controls. Those with GH deficiency reported lower QoL, as 
assessed by the HSCL and NHP questionnaires. The severity of their distress correlated 
positively with the duration of GH deficiency. Twenty-one of the patients entered a cross­
over, double blind, placebo-controlled study of the effects of GH replacement (0.25 
lU/kg/week; 12.5 pg/kg/day) on these measures. The HSCL score improved during the 
placebo phase, but fell further during active treatment. Active treatment was associated 
with improvement in the energy and emotional subsections of the NHP. In addition, spouses 
of the patients reported improved mood and behavior in the subjects during the GH 
treatment phase. An uncontrolled study with a small sample size suggested that GH 
replacement may result in improved memory in adults with GH deficiency (203).
The direct mechanisms behind alterations in perceived QoL remain unknown. Recently, 
treatment of GHD adults has been shown to alter levels of vasoactive intestinal polypeptide 
and the dopamine metabolite, homovanillic acid, as well as elevate B-endorphin levels in 
the cerebrospinal fluid, but whether these changes are responsible for improvements in 
mood and well-being is not yet known (204). GH, IGF-1, and the IGF-binding proteins may 
have direct effects on the nervous system. In addition, abnormal sleep patterns have been 
described in GH-deficient adults, with restoration to normal patterns after GH replacement 
(205, 206).
In summary, some studies showed definite benefit after patients received GH replacement 
therapy, but in others improvements were more limited or no improvement was seen (207),
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(208), (196), (195), (163), (209). The degree of improvement in quality of life is generally 
proportional to the deviation from normality at the outset (210, 211) but shows no 
correlation with the degree of improvement in IGF-1 levels (196). In practice, this means 
that if the patient’s quality of life is normal at baseline, no improvement will be seen with 
GH replacement (209). This is shown in the NICE guidelines for the management of 
AGHD in which rhGH is only recommended for patients who have demonstrated an 
impaired score of >11/25 on the QoL-AGHDA questionnaire^ 12), It has also been shown 
that much of the improvement in quality of life occurs within the first 3 months of GH 
replacement (211, 213), However, some long-term studies have shown sustained benefit in 
some aspects of quality of life among treated patients as compared with untreated patients 
(214).
SECTION 4: THE GROWTH HORMONE RECEPTOR AND THE GROWTH 
HORMONE RECEPTOR GENE
The growth hormone receptor gene (GHR) is the principal regulator of growth hormone 
(GH) sensitivity in health. It is a single membrane-spanning cell surface protein member of 
the class 1 cytokine receptor super-family. The human GHR gene consists of 9 coding 
exons (numbered 2-10) spanning at least 87kb of chromosome 5. Exon 2 encodes the signal 
peptide; exons 3-7 encode the extracellular domain made up of 246 amino acids; exon 8 
encodes the single transmembrane domain; and exon 9 and part of exon 10, the intracellular 
or cytoplasmic domain.
There are 2 isoforms of GHR in humans, generated by retention or exclusion of exon 3 
during splicing: a full-length isoform and an isoform that lacks exon 3 (GHR-d3). The 
generation of 2 transcripts that differ by the skipping of a coding exon results from 
homologous recombination, which mimics alternative splicing between the 2 retroviral 
sequences that flank the skipped exon(215). The allele encoding GHRd3 is specific to
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humans. Results of the studies of Pantel et al, 2003(216) supported the hypothesis that the 
GHRd3 isoform is transcribed from a GHR allele carrying a genomic deletion of exon 3 
rather than by alternative splicing.
Mutations at the level of the GH receptor
Subtle mutations in the growth hormone 1 (GH1) gene have been regarded as a 
comparatively rare cause of short stature. Mutations in the GHR gene have been 
demonstrated as the cause of Laron syndrome, also known as the growth hormone 
insensitivity syndrome (GHIS)(217). A number of point mutations have been identified in 
this gene: missense, nonsense and abnormal splicing. Most of the mutations are in the 
extracellular domain of the GHR.
A large number of mutations have already been identified in the GHR gene of patients with 
growth hormone insensitivity. None of these defects which are spread over the entire GHR 
gene sequence involves exon 3. The functional importance of the GHR domain encoded by 
exon 3 remains unknown(218).
A: POLYMORPHISM OF EXON 3 OF THE GHR GENE
The GHR is an obvious candidate gene to influence the response to rhGH. GH is a major 
determinant of postnatal growth and GHR mediates the majority of GH actions (219).
The GHR consists of an extracellular domain of 246 amino acids, a single transmembrane 
domain and a cytoplasmic domain. The encoding gene has 9 exons, but there are 2 
isofonns of the GHR in humans generated either by deletion of exon 3 of the gene resulting 
in 3 genotypes (220):
• full-length isoform only with retention of exon 3 on both alleles, i.e. homozygous 
GHR/? (full-length GHR - GHR/7; NM_000163);
53
short isoform only with exclusion of exon 3 on both alleles, i.e. homozygous
GHRd3 (exon 3 deleted GHR - GHRc/i; AF210633); and
an approximately 1:1 combination of the 2 isoforms, i.e. heterozygous GWR-d3/fl.
A
GHRfl allele s-c
Exon 3
GHRd3 allele s—{
935 bp
.3’
532 bp
Figure 1.6: Isoforms of exon 3 of GHR gene
[Source: Adapted from Pantel et al. J Clin Endocrinol Metab 2003 88(4): 1705-1710.] (216)
Population studies have shown that the heterozygote frequency is between 25-40%, while 
the GHR-d3/d3 genotype occurs in 7-15% of the population (3, 216, 221, 222). The two 
isoforms of GHR, are expressed in the placenta and appeared to be due to alternative 
splicing. The importance of the region coded for by exon 3 is unknown. The region is 
conserved in GHR proteins in mammalian species but is absent in prolactin receptor. This 
pattern of evolutionary conservation suggests that the loss or retention of exon 3 could 
affect receptor expression or function, specifically by affecting binding of human growth 
hormone, receptor processing, transport, stability, binding to other ligands, dimerization of 
GHR monomers or signal transduction. After the dimerization of the two transmembrane 
chains to form functional GHR, homozygous individuals have either GHR:/7 or GHR-Ji 
homodimers on their cell surfaces, whereas heterozygotes have GHR:/7 homodimers, GHR- 
d3 homodimers and GHR-d3/fl heterodimers. Its prominent function in growth hormone
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signalling and the frequency of its polymorphic variation makes GHR a good candidate for 
gene involvement in the pharmacogenomics of growth hormone therapy.
Stallings-Mann et al (2) found no change in the expression of the short form when 
placentas from different stages of gestation were examined, suggesting that splicing was 
not developmentally regulated. However, when isoform expression patterns were examined 
in each component of a given placenta, it was evident that alternative splicing of exon 3 is 
individual-specific. Surprisingly, this appears to be the result of a polymorphism in the 
GHR gene. Analysis of the expression of the full-length and short forms found results 
consistent with simple Mendelian inheritance of 2 differing alleles in which exon 3 is 
spliced in an 'all or none1 fashion(2). It was concluded that the alternative splicing of exon 3 
in GHR transcripts is the result of an unusual polymorphism that significantly alters 
splicing of the transcript, and that the relatively high frequency (approximately 10%) of 
homozygosity for the allele producing transcripts lacking exon 3 suggests the possibility 
that it may play a role in polygenically determined events, i.e., may have a selective 
advantage under some circumstances. A genetic polymorphism resulting in deletion of an 
entire exon from an mRNA without compromising structure or function of the resultant 
protein is unusual. Stallings-Mann et al (2) noted that exon 3 encodes a segment of the 
extracellular domain that is 22 amino acids long, and its removal results in the substitution 
of an aspartic acid for the alanine residue at the junction of exons 2 and 4. Exon 3 is not 
highly conserved among GHRs, and a homolog does not exist in the closely related 
prolactin receptor (OMIM 176761). Placentas showing homozygosity for the deletion were 
obtained from women who gave birth to apparently normal children.
The relevenace of exon 3 polymorphism in clinical practice
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After Pantel et al (220), identified polymorphism of exon 3 of the GHR gene in 2000, there 
have been several studies to try to determine its clinical significance. Those studies have 
tried to determine the effect of exon 3 polymorphism of the GHR on response to growth 
hormone therapy, in children with short stature and those with growth hormone deficiency. 
A number of studies in children have shown that this polymorphism may influence GH 
sensitivity during rhGH therapy for GH deficiency (GHD), Turner’s syndrome, idiopathic 
short stature and those born small-for-gestational age. The subjects with the d3/d3 or d3/fl 
genotype demonstrated a superior growth response during rhGH therapy compared to those 
with the fl/fl genotype (3, 221, 223, 224). However, there are also a number of studies in 
similar patient populations where this association was not observed, and thus the true effect 
of this polymorphism on GH sensitivity in rhGH treated children remains uncertain (222, 
225). It has been demonstrated in multiple studies that this polymorphism does not 
influence final adult height in healthy subjects (226, 227).
Adults with GHD demonstrate highly heterogeneous biochemical and clinical responses to 
GH replacement therapy.
Some patients seem to have little improvement in quality of life and body composition 
from GH therapy despite increases in the serum IGF-1 into the normal range, while other 
patients with untreated severe GHD are asymptomatic.
It is possible that these different clinical responses to GH in adults with GHD reflect a 
spectrum of GH sensitivity which may be related to the polymorphism of the GHR gene.
There have also been various studies to determine the significance of this polymorphism in 
other clinical scenarios other than GHD. Schmid et al determined that d3-GHR 
acromegalic patients had lower GH levels (228). Bernabeu’s study of 44 acromegalic 
patients determined that the deletion of exon 3 led to better response to pegvisomant
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therapy(229) while recent review of 127 patient by Filopanti et at showed no association 
between d3GHR and response to PEG-V therapy(230). Wassenaar et al on the otherhand 
determined that in patients with long-term cured acromegaly, the d3-GHR polymorphism 
was associated with an increased prevalence of irreversible comorbidities of 
acromegaly(231).
Studies reviwing the effect of the polymorphism on cardiovascular markers have shown 
association with lower BMI and better glucose tolerance with d3-GHR(232). In a review of 
subjects with normal (NGT), impaired glucose tolerance (IGT) and type 2 diabetes, 
Strawbridge et al(233), demonstrated that the d3/d3 allele appeared to be preventive of 
T2DM. However, when other factors caused overt T2DM, the d3-GHR allele confers a 
phenotype indicative of metabolic disorder. This study supports the hypothesis that the two 
GHR alleles by their inclusion or exclusion of exon 3 are functionally different.
There associciation of this polymorphism to other clinical conditions such as polycystic 
overian syndrome(234), coronary artery disease(235) and breast cancer(236) have all been 
studied with varying results. Overall results from these studies have been inconclusive with 
no clear and consistent association between exon 3 polymorphism of the growth hormoe 
receptor gene and the above mentioned disease states.
To date, the functional importance of this common polymorphism is remains undetermined 
and with the polymprphism occurring late in primate evolutional6), the significance may 
be yet to be discovered.
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In this research study, we set out to investigate the frequency of this polymorphism and to 
determine its influence of response to rhGH in the local AGHD population using both 
quality of life and biochemical parameters.
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CHAPTER 2
SUBJECTS, MATERIALS AND METHODS
Subjects 
GHD Patients
Patients were recruited from the Endocrine Unit of the University Hospital Aintree NHS 
Foundation Trust and the Joint Neuroendocrine Service of the Walton Centre for 
Neurology and Neurosurgery (WCNN), both in Liverpool, United Kingdom. The WCNN is 
a tertiary referral centre for the Mersyside, North Wales and Cheshire regions of the UK. 
This neuroendocrine service is jointly run by consultant endocrinologists and a consultant 
neurosurgeon. Patients with various intracranial pathologies initially seen and managed either 
by surgery and/or radiotherapy by the neurosurgical team are referred to the endocrinologist for 
assessment and management of their residual endocrine function.
Diagnosis of hypothalamic-pituitary dysfunction would have been made from baseline 
measurements of the anterior pituitary hormones and dynamic pituitary function testing and if 
required, was done using glucagon stimulation test for assessment of ACTH and GH axes. 
Patients with hypothalamic- pituitary disease were identified to have severe GHD on the basis 
of a peak GH response of <9mU/l (<3ug/L) following the administration of Img 
subcutaneous glucagon (134, 147). Patients with impaired GH levels on dynamic testing and 
AGHDA score > 11/25 were offered rhGH as per current recommendations.
Consequently, the patients attending the WCNN service who have been diagnosed with 
GHD fall into 2 main groups:
1. GHD patients already receiving GH therapy
2. GHD patients without symptoms and not requiring therapy
One hundred and seventy-three white Caucasian patients with hypothalamic-pituitary 
disorders (mean age 50 years, range 16-75 years) were studied. The clinical history for all 
participants was documented from their medical notes.
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Control Population
A control group representative of the normal adult population in the United Kingdom was 
recruited from the local population in Liverpool. One hundred healthy volunteers were 
recruited from the University Hospital Aintree staff and relatives. All the volunteers were 
Caucasian adults. Volunteers were required to read an information leaflet (see appendix), 
fill a brief form detailing relevant medical history and sign a consent form. All recruited 
volunteers had no significant medical history and were not taking any medications that 
could alter GH secretion.
Inclusion Criteria for Patients
• Patients with multiple pituitary hormone deficiencies were eligible for inclusion if 
other hormone treatments were optimised,
• Patients with GHD aged 16-75years being managed in the Endocrine clinic at the 
University Hospital Aintree and also at the Joint Neuroendocrine Service at the 
Walton Centre for Neurology and Neurosurgery (WCNN).
• Healthy adult (aged 16-75years) volunteers were recruited for the control group.
Exclusion criteria for Patients
• Patients with other pathologies or receiving medications likely to impact on general 
well-being or body composition, including patients with known malignancies, 
patients receiving glucocorticoid therapy other than for hormone replacement.
• Patients who were unwilling to participate in the study.
• Patients who were unwilling to answer the questionnaires.
61
Ethics
Ethical approval was sought and obtained from the Local Research Ethics Committee for 
this study (Ref no: 06/Q1508/25). Written informed consent was obtained from all patients 
before inclusion in the study. The study was carried out in accordance with the Declaration 
of Helsinki (1989) of the World Medical Association.
Anthropometric measurements
Waist-hip ratio and waist circumference were measured by a single observer. Weight was 
measured using electronic scales in light clothing without shoes. Height was measured as 
the distance from the top of the head to the bottom of the feet (no shoes) using a fixed 
Harpendon stadiometer. BMI was calculated as the weight (kg) divided by the square of the 
height (m). Waist circumference (cm) was taken with a tape measure as the point midway 
between the costal margin and iliac crest in the mid-axillary line, with the subject standing 
and breathing normally. Hip circumference (cm) was measured at the widest point around 
the greater trochanter. The waist-to-hip ratio was calculated as the waist measurement 
divided by the hip measurement. Body mass index (BMI) and height standard deviation 
scores (SDS) were derived from normative data from the British white Caucasian 
population. The percentage of body fat was measured using a bioimpedance meter (Tanita® 
Bodyfat Analyzer model TBF-305; Tanita®, Tokyo, Japan).
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Figure 2.1: Model of Tanita,< Bodyfat Analyser model TBF-dfd305 used in this study
(Source of Image: www.bodyfatscalereviews.org)
Health Related QOL Questionnaires (see appendices)
Health-related Quality of life tools are the standard methods for determining symptoms of 
GHD in adults. In this study, QoL was measured in the study population using the disease 
specific QOL-AGHDA and other generic questionnaires previously validated in adults with 
GHD (158, 167). The order of completion was the same for all patients and the 
questionnaires were answered in a single session.
Adult Growth Hormone Deficiency Assessment (QoL - AGHDA) questionnaire (159)
The QoL-AGHDA is a uni-dimensional measure of quality of life, using the needs based 
model. The QoL-AGHDA is a disease-specific measure for use in adults with GHD. It has 
a maximum score of 25 with lower scores associated with better quality of life. The QoL- 
AGHDA has a an internal consistency of 0.93 and test - retest variability of 0.93(159).
Hospital Anxiety and Depression (HADS) questionnaire (237)
The HADS questionnaire and the Satisfaction Scale is a self-assessment scale which has 
been developed and found to be a reliable instrument for detecting states of depression and 
anxiety in the setting of hospital medical outpatient clinics. Higher scores on this scale are 
associated with worse quality of life.
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Life fulfilment Scale and Disease Impact Scale adapted for GHD patients(158)
This scale is based on methods previously described by Krupinski in 1980(238). The value 
of Krupinski's approach is the opportunity for patients to weigh the numerous aspects of 
their quality of life and assess the discrepancy between their actual and desired 
circumstances. The life fulfilment scale has been shown to be reliable and valid. Lower 
scores are associated with worse QoL. The Disease Impact Scale is to determine the impact 
of a chronic disease on the daily life of an individual and therefore this was only 
administered to the GHD patients and not to the control population.
10-cm Visual Analogue Scale (VAS) (239)
The 10cm VAS was used and modified for energy levels with patients giving scores based 
on how much energy they felt they had. This scale ranges from 0 cm (no energy) to 10 cm 
(full of energy). Low scores are associated with worse quality of life.
Treatment with recombinant human growth hormone (rhGH)
Hormone replacement in patients with multiple pituitary hormone deficiencies was 
optimized before assessment for rhGH treatment. If required on the basis of their anterior 
pituitary hormone profiles and the presence of DI, patients received standard pituitary 
hormone replacements such as hydrocortisone, thyroxine, sex steroids and desmopressin. 
Patients treated with rhGH fulfilled the National Institute for Clinical Excellence (NICE) 
guidelines of a score >11/25 on the AGHDA questionnaire to qualify for treatment. The 
asymptomatic patients were defined as having an AGHDA score <11/25, despite 
biochemical evidence of GHD and were not on rhGH (212).
Patients treated with rhGH were commenced on commercially available rhGH - 
Humatrope® (Eli Lilly), Norditropin SimplexX® (Novo Nordisk) or Genotropin® (Pfizer).
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Patient education and relevant treatment information was provided priror to 
commencement of therapy by a dedicated endocrine nurse at the Walton Diabetes Centre 
Patients were educated on how to administer the daily injections and were encouraged to 
maintain contact with the endocrine nurse over the initial weeks of therapy. The starting 
dose of rhGH in adults with GHD was 0.3 mg/day by subcutaneous injection. Dose titration 
was done in the first three months to achieve an IGF-1 level reference range for sex and 
gender. Maintenance dose was then given for the next 6 months when a re-evaluation of the 
patients is recommended (212).
Methods
Patients with GHD were recruited consecutively from the neuro-endocrine clinic at 
University Hospital Aintree. Volunteers from the hospital environment were also recruited. 
Exon 3 expression of the GHR gene was determined in all participating groups. All patients 
and volunteers received written information about the study and written informed consent 
was obtained (see appendices).
Genetic studies were performed under the supervision of Professor M. Pirmohamed at the 
University of Liverpool. Genomic DNA was obtained from lymphocytes isolated from 
peripheral blood. A sample of 9ml of blood was collected from the participants into an 
EDTA bottle and determination of the genotype at the GHR-exon 3 locus of the gene was 
by PCR based techniques.
DNA was made available to undertake in the future more extensive analysis of other single 
nucleotide polymorphisms (SNPs) and haplotypes in the GHR gene, and relate these to the 
clinical parameters. Future studies looking at downstream genes regulating the actions of 
the GHR may also be possible in the future.
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DNA EXTRACTION
Reagents used for DNA Extraction and Amplification 
Triton Lysis Mix
Buffer A: 1M Sucrose (MW = 342.3 g/mol)
To make one litre of 1M sucrose, 342.3g of sucrose was dissolved in one litre of distilled 
water (dHiO). The solution was heated in a hot water bath to dissolve all sucrose and then 
autoclaved.
Buffer B: 200mls 1M Tris (pH 7.5) + lOOmls 1M MgCl2+ 200mls Triton X
To make 1L of 1M Tris, 121.14g of Tris was dissolved in 1 litre of dH20 giving a
molecular weight (MW) of 121.14g/mol.
To make 1L of 1M MgCI2, 203.3Ig of MgCl2 in 1 litre of dH2G giving a MW of 203.31 
g/mol. The mixture was then autoclaved.
To make the Triton Lysis Mix, 25 mis of Buffer B was added to 1 litre of Buffer A (1:40 
dilution). The Triton Lysis Mix was made fresh for use each time.
Nuclear Lysis Buffer
To make 1 litre of nuclear lysis buffer, 43.8g of 0.75M sodium chloride (NaCl) (MW = 
58.4 g/mol) was added to 9.3g of 0.0025M EDTA (MW = 372.2 g/mol) and dissolved in 1 
litre of dH20 the solution was then autoclaved and stored at 4°C.
10% Sodium Dodecvl Sulphate (SDS) solution
Twenty grams (20g) of SDS was weighed in a fume hood and dissolved in 200ml of dH20. 
This was not autoclaved. It was stored at room temperature.
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Proteinase K
Proteinase K was purchased from Sigma (P2308 - lOOmg) and was packed as lOOmg 
powder. To make lOmg/ml solution, 10ml sterile (autoclaved) dHiO was added to the 
powder. Aliquots of 1ml solution were labelled into eppendorfs (minifuge tubes) and stored 
at -20° C.
6M NaCl Solution
NaCl with molecular weight of 58.4 g/mol was used. To make 1 litre, 350,4g of NaCI was 
dissolved in 1 litre of dlTjO and then autoclaved.
6M NaCl is a very saturated solution with crystal sediments. It does not dissolve even after 
heating in hot water bath.
Tris EDTA (TE1 Buffer
TE was purchased from Sigma (T9285 - 100ml 100X solution). TE powder containsl.OM 
Tris-HCL and 0.1M EDTA and has a pH of approximately 8.0. To make up at IX 
concentration of TE, 0.2ml (i.e. 200pl) of 100X Tris EDTA was dissolved in 20ml of 
sterile dHaO.
ReddvMix™ PCR Master Mix (1.5mM Mg Cl?)
PCR ReddyMix™ Master Mix is a ready-to-use master mix for amplifying DNA which 
removes the risk of contamination and pipetting errors. Each vial contains 1,8ml of l.lx 
working concentration PCR Master Mix sufficient for 40 x SOpl reactions. The addition of 
the template and primers results in a final reaction volume of 50pl, containing 
1,25 units Thermoprime Plus DNA Polymerase
75mM Tris-HCl (pH 8.8 at 25°C)
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20mM (NH4)2S04
1.5mM MgCl2
0.01% (v/v) Tween® 20
0.2mM each of dATP, dCTP, dGTP and dTTP
Precipitate and red dye for electrophoresis
Primers for DNA Amplification
DNA amplification was performed with a multiplex PCR procedure using the following 
primers: forward primer G1 (5'-TGTGCTGGTCTGTTGCTCTG-3'), [nucleotides 3285- 
3304] and reverse primers G2 (5AGTCGTTCCTGGG AC AG AG A-3'), [nucleotides 6534- 
6515] and G3 (5'-CCTGGATTAACACTTTGCAGACTC-3'), [nucleotides 4219-4196]. 
The Gl, G2 and G3 primers are described in GenBank accession no. API55912. DNA was 
amplified using a multiplex strategy described by Pantel et al(215). Primers were purchased 
at Invitrogen® and Certificate of analysis is shown in Appendix 7. The primers were 
diluted to 5pmol concentration and stored at -20oC.
HyperLadder® IV from Bioline
HyperLadder IV allows determination of molecular weight and DNA quantification and is 
specially designed for short fragments such as PCR products. HyperLadder IV produces a 
pattern of 9 regularly spaced bands, ranging from 100 to l,000bp. The 1,000 band has a 
higher intensity than the others to allow easy identification and each band is an exact 
multiple of lOObp.
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Procedure for DNA extraction:
DNA was extracted from whole blood which had been stored in EDTA bottles at -20°C. 
The blood was thawed for 30-45 minutes before use. One ml of blood was pipetted into a 
cryovial as reserve before starting any DNA extraction. In cases when the blood was 
partially clotted, it was first homogenised (by vortexing). The thawed blood was poured 
into a labelled plastic 50 ml falcon centrifuge tube and filled with ice cold sterile distilled 
H2O (i.e. autoclaved dlTjO). This was then placed on ice for 30 minutes and afterwards 
centrifuged at 6000 rpm for 15 minutes at 4°C. Care was taken to note that a pellet had 
been obtained first and then the supernatant was discarded. The pellet was re-suspended in 
25 mis of ice cold Triton lysis mix pH 7.7 using a pastette. This was again placed on ice for 
30 minutes and then centrifuged at 6000 rpm for 10 minutes at 4°C and the supernatant 
discarded. What was left was a clean, white pellet of nuclei. This pellet was re-suspended 
in 9 mis of pH 8.0 Nuclear Lysis buffer using a pastette. 500 pi of SDS (10%) and 200 pi 
proteinase K (10 mg/ml) were added. The powerful proteolytic activity of proteinase K 
combined with the denaturing ability of SDS lysed the white cell membranes and the 
nuclear membranes, thus releasing the DNA from the nucleus.
This was then incubated at 55°C for 3 hrs. Thereafter, if the preparation looked clean, 
(colourless, or yellow ringed) 1/3 volume of 6M NaCl was added and shook vigorously for 
20 seconds. This was then centrifuged at 6000 rpm at 4°C for 15 minutes. If it looked dirty, 
10 mis of Phenol: Choloroform 1:1 was added and the mixture spun for 10 mins at 6000 
rpm. The supernatant was removed and 1/3 vol. of 6M NaCl was added to it. This mixture 
was shaken vigorously for 20 seconds and then spun at 6000rpm at 4°C for 15 minutes.
The supernatant was carefully poured (or pipetted) into a clean labelled falcon centrifuge 
tube, taking care not to disturb the pellet and about 2 vols, of 100% ethanol was added. The 
tube was swirled fairly vigorously and the DNA precipitated out as a white clump. The
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DNA was carefully hooked out using a syringe with needle or pipette tip and placed in a 
minifuge tube. One ml of 70% ethanol was then added to wash the DNA, and shaken 
gently. This was spun at 5000 rpm for 1 minute to pellet the DNA. The ethanol was 
removed completely using a pipette tip. The DNA was then dried for 10 minutes at 37°C (It 
was important not to over-dry the DNA since it would not readily dissolve in TE) or left to 
dry in the safety cabinet at room temperature. 450 pi of sterile TE was added and stored at 
4°C for 2 weeks.
Measurement of DNA concentration and dilution
After 2 weeks, the DNA concentration was measured using a spectrophotometer. The UV 
and Vis were switched on and allowed to warm up for up to 1 hour. The cuvette was rinsed 
out with distilled water. lOOpl of lx TE was blanked in the metre. Then 2pl of DNA was 
added to lOOpl of IxTE in the cuvette and mixed well with a pipette tip. The absorbency at 
260nm was read and the mean of 3 readings was recorded. The A260/A280 ratio had to be 
greater than 1.7.
DNA Dilution:
Final stock DNA required was 20mg/pl (pg/ml) and final volume of DNA required was 
200pl. The amount of DNA required to make up 200pl solution was calculated.
The DNA solution was then stored at 4°C and the remaining DNA was stored at —20°C for 
future use.
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DNA extraction using Chemagen"
Genomic DNA was extracted from whole blood using magnetic bead technology and 
Chemagic Magnetic Separation Module I (Chemagen* Auto Q Biosciences Limited, 
Berkshire, UK) according to the manufacturer's protocol for 10 ml of blood.
Preparation of blood Lysate
Lypophilised protease was dissolved in water and stored at 4oC which was viable for4-6 
weeks. 50pl of protease was added to each tube containing 10ml of whole blood. 8ml of 
lysis buffer was then added. This mixture was commenced on lysate mixing for Chemagic 
DNA blood protocol for 20minutes. 28ml of binding buffer solution was then added to the 
lysate and then 1.2ml of magnetic beads. This mixture was commenced on automated 
isolation process according to Chemagic protocol. 1ml of DNA solution was then isolated 
and stored at 4°C.
DNA amplification with polymerase chain reaction (PCR)
lul ot 20ng/ul genomic DNA was added to 24ul reaction mixture (ReddyMix1N1 Master 
Mix, ABgene, UK) of 1.5mM MgC12, 0.5mM each dNTP, lul of 0.2mM of each primer. 
The cycling programme performed on a G-storm Thermal Cycler PCR machine (Licensed 
is from Applied Biosystems, California, USA) was as follows: denaturation for 2mins at 
94°C followed by 35cycles of 94°C for 30sec, 60°C for 30sec and 72°C for 90sec. This was 
followed by a final extension step of 7mins at 72°C. It was then cooled for 10°C for 
30mins.
The presence and size of amplification products was determined by electrophoresis on 1% 
agarose gel stained with ethidium bromide. 1% agarose was prepared using 0.5% tris borate 
EDTA (TBE). 0.8g of agarose was dissolved in 80ml of 0.5TBE. The mixture was
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dissolved and 8ng (lOmg/ml) ethidium bromide. The mixture is poured in an 
electrophoresis plate with comb trays inserted. When cooled the gel sets. The tank is filled 
with 0.5TBE then 12pl of amplified DNA solution in inserted in each well with one well 
containing 5pl of HyperLadderR IV from Bioline. The electrode is set at 100V for up to 30 
minutes.
The tl allele (GHR/7) is represented by a 935-bp fragment and the d3 allele (GHRdS) by a 
532-bp fragment. When a homozygous d3/d3 genotype was detected (a single band 
corresponding to 532-bp) and/or when a band potentially corresponding to 935-bp product 
was mildly amplified, a second PCR using G1 and G3 primers was carried out, which 
amplified GHR/7 alleles. Quality control assessment included using both positive and 
negative controls in each batch of samples (sample of alleles following electrophoresis 
shown in appendix).
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Figure 2.2: Genotype assay at the GHR exon 3 locus
(Source: J. Biol. Chem., Vol. 275, Issue 25, 18664-18669, June 23, 2000) (220)
A schematic representation of the human GHRfl region including exon 3 {black box) and the 
repeated elements {grey boxes) is shown in Figure 2.2. The GHRd3 allele contains a single copy of 
the repeat {grey box). The position and orientation of primers Gl, G2, and G3 used in the multiplex 
PCR assay are indicated by arrowheads. B. under specific experimental conditions {i.e. 
denaturation 94 °C, 30 s; annealing 60 °C, 30 s; and elongation 72 °C, 90 s), primers Gl and G2 
allowed the amplification of GHRd3 alleles only, whereas primers Gl and G3 amplify GHRfl 
alleles. The homozygous GHRfl, heterozygous GHRfl/GHRd3 and homozygous GHRd3 genotypes 
are denoted by//, d3/fl, and d3< respectively.
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Figure 2.3: Electrophoresis of PCR amplified DNA fragments. The 935-bp band indicates fl allele, the 
532-bp band indicates the d3 allele (240)
Hormone measurements
Serum GH levels were measured following the administration of Img subcutaneous 
glucagon (glucagon stimulation test) in all GHD patients prior to commencement of rhGH 
therapy. Serum GH and IGF-1 levels were analysed in the hospital laboratory using 
chemiluminescent immunometric assays using IMMULITE 2000 (Siemens Medical 
Solutions Diagnostics).
Statistical analysis
Results are expressed as percentages and mean ± SD. Continuous data analysis for a 
difference among the GHRdS/GHRfl genotypes was calculated using ANOVA (with post- 
hoc Bonferroni correction for multiple testing). Categorical data analysis including the 
GHR(J3/GHRfl allelic and genotype frequencies was performed by the chi-square test. 
Statistical analyses were performed using SPSS 15.0 for Windows.
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CHAPTER 3
ASYMPTOMATIC GROWTH HORMONE DEFICINECY
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Introduction
Two sets of GHD patients are seen in our clinic population; a treated group on rhGH and an 
asymptomatic group not requiring GH replacement therapy.
In clinical practice, decision on who to commence on rhGH is based on the QoL-AGDHA 
questionnaire. Patients would have fulfilled National Institute for Clinical Excellence 
(NICE) guidelines of a score >11/25 on the QoL-AGHDA questionnaire to qualify for 
treatment. Scores of >11 are often associated with tiredness, fatigue, mood lability and 
reduced quality of life. When multiple pituitary hormone deficiencies exist, all other 
deficient hormones need to be replaced and optimized before patients are assessed for 
rhGH treatment.
An interesting group of patients however score low on the QoL-AGHDA, that is, <11/25 
score despite biochemical evidence of severe GHD (i.e. peak GH response during glucagon 
stimulation testing < 3ug/L), These asymptomatic patients do not require treatment 
according to current NICE guidelines.
It is not known why some patients appear not to have impairment in their quality of life 
despite sometimes very significantly severe growth hormone deficiency. The obvious gene 
to investigate is the GHR which is the principal regulator of growth hormone (GH) 
sensitivity. Polymorphism of exon 3 of the GHR has been shown to influence response to 
human recombinant growth hormone therapy (rhGH) with patients homozygous or 
heterozygous for exon 3 deletion, d3/d3 or d3/fl showing better response to treatment. In 
patients with asympotomatic GHD, could a higher prevalence of exon 3 deletion improved 
adaptability to low levels of GH and thus no exhibition of impaired QoL despite 
biochemical deficiencies?
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We hypothesized therefore that a higher prevalence of exon 3 deletion may exist among 
this population of asymptomatic patients with GHD.
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Subjects and Methods 
Patients
One hundred and seventy-three white Caucasian patients with hypothalamic-pituitary 
disorders (mean age 50 years, range 16-75 years) were studied. All patients had severe 
GHD defined as peak GH <9mU/I (<3ug/L) following the administration of Img 
subcutaneous glucagon (134, 147), The clinical history for all participants was 
documented from their medical notes.
Health related QOL questionnaires
Quality of life tools are the standard methods for determining symptoms of GHD in adults. 
QoL was measured in the study population using 4 validated questionnaires: the Adult 
Growth Hormone Deficiency Assessment (AGHDA) questionnaire(159), the Hospital 
Anxiety and Depression (HADS) questionnaire, the Life fulfilment Scale and Disease 
Impact Scale adapted for GHD patients(158). Finally, energy levels were determined using 
a 10-cm Visual Analogue Scale (VAS). The order of completion was the same for all 
patients and the questionnaires were answered in a single session. Higher scores are 
associated with worse quality of life in the AGHDA questionnaire, the HADS and the 
Satisfaction Scale, and lower scores with worse QoL or energy levels in the Disease Impact 
Scale and VAS, respectively.
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GH replacement therapy
Hormone replacement in patients with multiple pituitary hormone deficiencies was 
optimized before assessment for rhGH treatment. Treated patients fulfilled the National 
Institute for Clinical Excellence (NICE) guidelines of a score >11/25 on the AGHDA 
questionnaire to qualify for treatment. The asymptomatic patients were defined as having 
an AGHDA score <11/25, despite biochemical evidence of severe GHD and were not on 
rhGH.
Genotyping and hormone measurements
Genomic DNA was extracted from lOmls whole blood using magnetic bead technology 
and Chemagic Magnetic Separation Module I. DNA was amplified using a multiplex 
strategy. The Gl, G2 and G3 primers are described in GenBank accession no. AF155912. 
The fl allele (GHR/7) is represented by a 935-bp fragment and the d3 allele (GHRd3) by a 
532-bp fragment. Quality control assessment used both positive and negative controls in 
each batch of samples. Serum GH and IGF-1 levels were analysed in the hospital 
laboratory using chemiluminescent immunometric assays.
Statistical analysis
Results are expressed as percentages and mean ± SD. Continuous data analysis for a 
difference among the GHRdSIGHRfl genotypes was calculated using ANOVA (with post- 
hoc Bonferroni correction for multiple testing). Categorical data analysis including the 
GHRd3IGWRfl allelic and genotype frequencies was performed by the chi-square test. 
Statistical analyses were performed using SPSS 15.0 for Windows.
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Results
Population studies
Of the 173 patients studied, 131 were treated with rhGH for impaired QoL. The remaining 
42 patients were asymptomatic and did not require rhGH replacement. The mean age of the 
entire study population was 51 (±13) years with a mean duration since diagnosis of GHD 
13 (±10) years. There was a male preponderance of 57% in the population. Tables 3.1, 3.2 
and 3.3 show the primary diagnoses, previous treatments, other medical conditions and 
hormone replacement in the two patient groups.
Comparison of QoL scores between asymptomatic patients and GHD patients
Table 3.4 shows the comparison of measured variables and QoL scores between the 
asymptomatic patients and those on rhGH. The asymptomatic patients have significantly 
better QoL scores despite having significantly lower IGF-1 levels. There was however no 
significant difference in the WHR, BMI and percentage body fat mass between the two 
groups.
GHR-genotype frequencies and effect of the GHR d3/fl genotypes
Ninety five patients (55%) were homozygous for /////, 65 (37%) were heterozygous d3/fl 
and 13 (8%) were homozygous d3/d3. Table 3.5 shows the distribution and frequency of 
the different genotypes in treated and untreated populations. There was no significant 
difference in distribution between the rhGH treated patients and the asymptomatic patients. 
Table 3.6 shows the comparison between the genotypes for the whole study population. 
This comparison includes their peak GH levels at presentation, the rhGH dose required to 
optimize their serum IGF-1 levels (for patients on treatment), their present QoL scores and 
body composition. There was no significant difference in any of the parameters between
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genotypes both with the d3 isoforms pooled together and analysed separately except for the 
depression scale among the asymptomatic patients.
Body composition and QoL were compared between genotype groups for patients treated 
with rhGH and asymptomatic patients (Table 3.6). The asymptomatic GHD patients with 
the d3 isoform had significantly lower depressions scores than those with the fl/fl isoform. 
However, no other differences in QoL scores were found in the d3 isoform patients 
compared to the fl/fl patients in the treated and untreated populations.
Discussion
Controversy exists as to the role of the GHRd3 polymorphism on the response of GHD 
patients to treatment. Some studies in children have demonstrated a superior growth 
velocity in individuals with the d3 isoform(3, 224, 241) while other studies report there is 
no significant difference between these groups(222, 225). For GHD adults in the United 
Kingdom, apart from biochemical evidence of GHD, the decision to commence and 
continue treatment are based on the demonstration of impaired QoL from NICE approved 
validated questionnaires. Two sets of GHD patients are seen in our clinic population; a 
treated group on rhGH and an asymptomatic group not requiring GH replacement therapy. 
In this study, we speculated that adult GHD patients with exon 3 deletion are less likely to 
be symptomatic from GHD than those without. We therefore studied the relationship 
between QoL, the need for rhGH therapy and deletion of exon 3 in the GHR gene. We were 
also investigated the relationship between exon 3 deletion and other markers of GHD: 
serum IGF-1 prior to rhGH therapy and anthropometric measures.
The prevalence of the three GHR d3 genotypes in this population was comparable to 
previous studies in which up to half of the population is homozygous for the fl allele (221,
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242, 243). As previous studies in childhood suggest that patients who delete exon 3 on one 
or both alleles (d3/fl and d3/d3) have a similar growth response to rhGH, data from these 
patients were analysed together and separately. The results of this study do not support our 
hypothesis that patients with the d3/fl or d3/d3 genotype are less likely to need rhGH 
therapy to improve quality of life than those with the fl/fl genotype (shown in Table 3.4). 
The difference in depression scale between the two genotype groups is probably of no 
clinical significance because scores of 0 to 7 on the HADS-depression scale are classed as 
normal with 8 to 10 being borderline normal and 11 to 21 being abnormal(237). Data from 
this study also suggest that the GHR-d3 polymorphism does not influence stimulated GH 
levels prior to rhGH therapy or body composition.
This study suggests that in the adult population with GHD factors other than the GHR d3 
polymorphism influence the QoL. There are multiple causes of hypopituitarism in GHD 
adults and patients receive multiple and prolonged treatments, attending regular and 
repeated follow-up MRI/CT scanning which, in themselves, generate anxiety. As a result, 
determinants of QoL in adults are probably multi-factorial and may in fact be difficult to 
relate to a single cause such as the GHR<73 polymorphism. Coexisting medical conditions 
are also likely to impact on QoL. It is also important to observe that while in children, 
response to treatment is easily measured by growth velocity, QoL measures remain the best 
way of monitoring response to treatment in adults with GHD. However in many patients, 
QoL is difficult to measure and interpret, and may lack sensitivity.
The data show that despite adequate hormone replacement, patients on rhGH continue to 
have suboptimal QoL. This has been reported in previous studies showing that the QoL 
scores improve and then plateau after a few years on treatment (126, 167). Both
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populations of GHD patients have multiple hormone deficiencies and are receiving other 
hormone replacements.
To date, results relating the GHRJ3 polymorphism and growth hormone response are 
inconclusive. Further studies are needed to investigate this and other polymorphisms in 
both children and GHD adults. In conclusion, we have demonstrated that the deletion of 
exon 3 in the GHR gene does not influence QoL and energy levels in adults with GHD.
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Table 3.1: Diagnoses and previous treatments of the 42 patients with asymptomatic 
severe GHD
Diagnosis Total Surgery Irradiation
Non-functioning Pituitary 17 16 7
adenoma
Craniopharyngioma 2 1 1
Prolactinoma 8 4 4
Pituitary apoplexy 5 2 -
Miscellaneous 10 4 6
Miscellaneous: 1 Cushing's disease,IRathke’s cyst, 1 acromegaly, 1 empty sella, 1 
arachnoid cyst, 1 chordoma, 1 hypothalamic harmatoma, 1 pineal tumour,! suprasellar 
tumour and 1 cerebral seminoma
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Table 3.2: Primary diagnosis and previous treatments of the 131 patients treated with 
rhGH
Diagnosis Total Surgery Irradiation
Non-functioning Pituitary
adenoma
45 42 22
Craniopharyngioma 23 19 11
Prolactinoma 11 4 3
Pituitary apoplexy 4 1 0
Rathke's cyst 3 3 0
Astrocytoma 4 2 4
Medulloblastoma 4 4 4
Miscellaneous 37 20 19
Miscellaneous: Cushing's disease, acromegaly, empty sella syndrome, arachnoid cysts, chordoma, 
idiopathic isolated GHD, glioblastoma, thalamic tumour, meningioma, Langerhan's cell 
histiocytosis, HSV encephalitis, pineal tumour, septo-optic dysplasia, nasopharyngeal 
neuroblastoma
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Table 3.3: Coexisting medical conditions and hormone deficiencies of the 173 GHD 
patients
Asymptomatic
GHD
n=42
GHD patients
on rhGH
n=131
Replacement therapy
Corticosteroids 25 [60%) 91 [69%)
Thyroxine 24 [57%) 79 [60%)
Sex Hormones 22 [52%) 83 [63%)
DDAVP 4 [10%) 28 [21%)
Dopamine Agonists 9 [21%) 12 [9%)
Total hormone replacement 2 [5%) 20 [15%)
Coexisting Medical Conditions
Diabetes Mellitus 2 [5%) 5 [4%)
Hypertension 12 [29%) 34 [26%)
Dyslipidaemia 24 [57%) 74 [56%)
Epilepsy 2 [5%) 12 [9%)
Previous CVA 1 (2%) 6 (5%)
Ischaemic Heart Disease 2 [5%) 7 [5%)
Asthma 1 [2%) 6 [5%)
Morbid Obesity 1 [2%) 5 [4%)
Osteoarthritis 2 [5%) 4 [3%)
Anxiety/depression - 3 (2%)
Severe COPD - 2 [2%)
Peripheral Vascular Disease 1 (2%D 1 [1%)
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Table 3.4: Comparison of measured parameters in treated and asymptomatic patients
Asymptomatic
GHD
n=42
GHD on
treatment
n=131
p value
Gender (m:t] 27:15 71:60
Age [years] 56[16] 50(12] p=0.01
Mean duration of GHD 11[7] 13(10] NS
[years]
Peak GH [mU/1] 1.9[1.9] 2.6(2.9] NS
Serum IGF-1 at diagnosis 11.1 [4.8] 12.4(4.7] NS
of GHD [nmol/L]
Current serum IGF-1 12.0[5.1] 25.5(11.6] p<0.001
[nmol/L]
QoL
AGHDA 5(5] 10(7] p<0.001
HADS-depression 4(4] 7(5] pcO.OOl
HADS- anxiety 4(2] 7(4] p=0.001
LFSS 43(4] 42(4] NS
Satisfaction scale 21(5] 25(5] p<0.001
VAS energy scale [cm] 7.4(2.1] 5.7(2.1] pcO.OOl
Measurements
Height [SDS] -0.50(1.4] -0.40(1.3] NS
BMI[SDS] 2.2(1.1] 2.1(1.0] NS
WHR 0.97(0.1] 0.93(0.1] NS
Body Fat [%) 31.6(10.4] 34.8(9.5] NS
Significance p<0,05, NS - not significant. Data are presented as wean (SD)
HADS - hospital anxiety and depression scale, LFSS- life fulfilment and satisfaction scale, VAS-visual 
analogue scale, BMI- body mass index, WHR- waist-hip ratio.
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Table 3.5: Frequency of genotypes in the study population
Genotype Asymptomatic GHD
n=42
GHD on treatment
n=131
fl/fl 55% 55%
d3/fl 33% 39%
d3/d3 12% 6%
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Table 3,6: Comparison of QoL scores and measured variables between genotype 
groups in treated and asymptomatic patients (n=173)
Measured variables
GHR genotype
fl/fl d3/fl or d3/d3 p value
Frequency
On rhGH 72 59 Ns
Asymptomatic 23 19 Ns
Age (years)
On rhGH 49 (12) 51 (12) Ns
Asymptomatic 55 (17) 56(13) Ns
Peak GH (^ diagnosis (mU/I)
On rhGH 2.7 (3.4) 2.4 (2.2) Ns
Asymptomatic 1.7 (2.0) 2.0 (1.8) Ns
rhGH Dose (mg) On rhGH 0.52 (0.6) 0.36 (0.2) Ns
Serum IGF-1 (^diagnosis (nmol/1)
On rhGH 13.3 (5) 11.1 (4.1) Ns
Asymptomatic 10,3 (4) 11.4 (5.1) Ns
Serum IGF-1 (nmol/1)
On rhGH 25.5 (12) 25.5 (11.5) Ns
Asymptomatic 11.4 (5) 12.7 (5.3) Ns
QoL
AGHDA
On rhGH 9(6) 10(7) Ns
Asymptomatic 5(4) 5(5) Ns
HADS-depression
On rhGH 6(5) 8(5) Ns
Asymptomatic 5(4) 2(2) 0.02
IIADS- anxiety
On rhGH 6(4) 7(5) Ns
Asymptomatic 3(2) 4(3) Ns
LFSS
On rhGH 42(4) 41(4) Ns
Asymptomatic 43(4) 43 (4) Ns
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GHR genotype
Measured variables fl/fl d3/fl or d3/d3 p value
Satisfaction scale
On rhGH 24 (5) 25 (5) Ns
Asymptomatic 21(5) 20 (4) Ns
Disease Impact scale
On rhGH 26 (7) 24 (7) Ns
Asymptomatic 29 (7) 31(9) Ns
VAS energy scale (cm)
On rhGH 5.9 (2.0) 5.3 (2.2) Ns
Asymptomatic 7.3 (2.0) 7.6 (2.2) Ns
Measurements
Height (SDS)
On rhGH -0.51 (1.4) -0.24(1.2) Ns
Asymptomatic -0.31 (1.5) -0.73(1.3) Ns
BMI (SDS)
On rhGH 2.1 (1.1) 2.2 (1.0) Ns
Asymptomatic 2.2 (1.2) 2.3 (0.9) Ns
WHR
On rhGH 0.92 (0.1) 0.93 (0.1) Ns
Asymptomatic 0.98 (0.1) 0.95 (0.1) Ns
% Body Fat
On rhGH 34.2 (8.8) 35.7 (10.2) Ns
Asymptomatic 30.9(11.4) 32.7 (9.4) Ns
Significancep<0,05, NS - not significant, Data are presented as mean (SD)
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CHAPTER 4
EFFECT OF GHR GENE POLYMORPHISM ON ADULTS ON GROWTH 
HORMONE TREATMENT
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Introduction
A number of studies in children have shown that the GHR polymorphism may influence 
GH sensitivity during recombinant human GH (rhGH) therapy for GH deficiency (GHD), 
Turner’s syndrome, idiopathic short stature and those bom small-for-gestational age. Thus, 
subjects with the d3/d3 or d3/fl genotype demonstrated a superior growth response during 
rhGH therapy compared to those with the fl/fl genotype (3, 221, 223, 224). However, there 
are also a number of studies in similar patient populations where this association was not 
observed, and thus the true effect of this polymorphism on GH sensitivity in rhGH treated 
children remains uncertain. It can perhaps be stated with more certainty that this 
polymorphism does not influence final adult height in healthy subjects (222, 225,244). 
Growth hormone deficiency developing in adult life results in impaired quality of life 
(QoL) and altered body composition (BC). As in children, it is now standard practice to 
treat adult growth hormone deficiency with rhGH. In this study, we investigated GHD 
adults who have been treated with rhGH for more than one year, in order to determine the 
relationship between genomic deletion of exon 3 in the GHR gene and QoL, body 
composition and serum IGF-1 levels, and to compare these variables to a healthy adult 
control population.
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Materials and Methods
Patients
One hundred and thirty-one patients with GHD attending the endocrine clinic and receiving 
rhGH treatment for more than one year were studied. All the patients studied were white 
Caucasians. All patients had severe GHD defined as peak GH < 9mU/l (3ug/L)(212) after 
Img subcutaneous glucagon(134, 147). The clinical history was documented from 
medical records.
Controls
A control group of 100 healthy white Caucasian adult volunteers from the local population 
were recruited for the study. The volunteers had no significant past medical history, family 
history of pathologic short stature and no previous or existing pituitary disease. They were 
assessed using the same QoL instruments as the GHD patients and their body composition 
and GHR genotypes were also determined.
Health related QOL questionnaires
QoL was assessed in both the patient and control populations using 4 validated 
questionnaires: The National Institute for Clinical Excellence (NICE) approved 
questionnaire tor treatment of GHD, the Adult Growth Hormone Deficiency Assessment 
(AGHDA) questionnaire(159), the Hospital Anxiety and Depression (HADS) 
questionnaire, the Life fulfilment Scale and the Satisfaction and Disease Impact Scale 
adapted for GHD patients(l 58). The volunteers were not required to fill in the Disease 
Impact scale questionnaire. Finally, a 10-cm Visual Analogue Scale (VAS) was also used 
to determine energy levels. The VAS scoring ranged from 0cm (no energy) to 10cm (full of 
energy). This tool has been used in previous studies of adult GHD patients(167). Higher
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scores are associated with worse quality of life in the AGHDA questionnaire, the HADS 
and the Satisfaction Scale, and lower scores with worse QoL and energy levels in Disease 
Impact Scale and VAS, respectively. The order of completion of questionnaires was 
consistent and all questionnaires were answered in a single session.
GH treatment
Patients with multiple hormone deficiencies were adequately replaced and treatment 
optimized prior to commencement of rhGH according to existing national treatment 
guidelines(245). All patients had also fulfilled NICE guidelines of a score >11/25 on the 
AGHDA questionnaire before commencing treatment(212).
Genotyping and hormone measurements
Genomic DNA was extracted from lOmls whole blood using magnetic bead technology 
and Chemagic Magnetic Separation Module I. DNA was amplified using a multiplex 
strategy. The Gl, G2 and G3 primers are described in GenBank accession no. AF155912. 
The fl allele (GHR//) is represented by a 935-bp fragment and the d3 allele (GHRd3) by a 
532-bp fragment. Quality control assessment used both positive and negative controls in 
each batch of samples. Serum GH and IGF-1 levels were analysed in the hospital 
laboratory using chemiluminescent immunometric assays.
Statistical analysis
Results are expressed as percentages and mean ± SD. Differences between the variables 
evaluated among the GHRdS/GHRfl genotypes were calculated using ANOVA 
(Bonferroni). Differences for the GHRd3lGFIR/7 genotype frequencies were analyzed by 
the chi-square test. Data were analyzed using SPSS 15.0 for Windows.
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Results
Population studies and GHR-genotype frequencies
One hundred and thirty-one GHD patients who had been treated with rhGH for more than 
one year were studied, of whom 71 (54%) were male. The age of the patient population 
was 50 (±12) years and the mean duration since primary diagnosis in the patient population 
was 12 (±10) years. One hundred and two patients (78%) had structural hypothalamic- 
pituitary disorders and sixty-three (48%) of the patient population had received 
hypothalamic irradiation. Table 4.1 shows the aetiology of GHD in the patients studied. 
Table 4.2 shows the coexisting medical conditions and hormone replacement therapies. 
Figure 4.1 shows the distribution and frequency of the different genotypes in patients and 
controls. Seventy-two patients (55%) were homozygous for the wild-type allele (fl/fl), 
51(39%) were heterozygous for the allele coding the d3 isoform (d3/fl) and 8 (6%) were 
homozygous {d3/d3). Of the 100 healthy adult controls, 44% were males with a mean age 
of 45 (±13) years. The frequency of the genotypes was 53% (fl/fl), 40% (d3/fl) and 7% 
(d3/d3). There was no significant difference in the frequencies of these alleles between the 
patient and control populations.
Comparison of study population between GHR genotypes
The study populations (patients and controls) were divided into 2 genotype groups, with the 
d3 homozygous and heterozygous isoforms grouped together. Comparison was made 
between the clinical and laboratory parameters and QoL scores between the 2 groups for 
both patients and controls. There was no significant difference in the measured variables 
based on the genotype in the patient population except for the LFSS scale (Table 4.3). 
Similarly in the control population there was no difference in QoL scores and clinical 
parameters between the different genotypes (not shown). Further analysis of both
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population genotypes grouped separately (Le. fl/fl, d3/fl and d3/d3) still showed no 
significant difference in measured variable.
Further analysis of the volunteer population was carried out to determine the frequency of 
the genotypes in the extremes of height (i.e. SDS<2.0 and >2.0); no significant difference 
in the extremes of height was identified.
Comparison of QoL scores between patient and control population
Comparison of measured variables and QoL scores was undertaken between the treated 
GHD patients and the healthy adult controls (shown in Table 4.4). There were significantly 
better QoL scores in the control population as compared to the patient population despite 
being on replacement therapy. Measurements of BMI and height were expressed in mean 
(SD) standard deviation scores (SDS) for normal adult Caucasian population. Both 
populations were of similar height, but the GHD patients had a significantly higher BMI 
and WHR than the control population.
Discussion
Despite several recent publications in the paediatric population, there has been very little 
interest in the role of polymorphisms in the GHR gene and response to GH therapy in the 
adult population. Studies investigating the exon 3 polymorphism in the adult population^, 
246) did not address QoL which remains the main indication for the use of rhGH in the 
United Kingdom, This study aimed to determine the prevalence of the polymorphism of 
exon 3 of the GHR in the local population and also to analyze whether a relationship exists 
between genotypes GHR-r/i/r/i, GHR-cU///, and GHR-///// and QoL, body composition and 
serum IGF-1 levels in GHD adults on stable GH replacement.
A total of 100 healthy Caucasian adults were studied and the prevalence of the GHR-d3 
polymorphisms was comparable to previous studies showing up to half of the population
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being homozygous for the // allele. Similar frequencies were also seen in the patient 
population. Previous studies have shown that growth response in GHD children is greater 
in children who exclude exon 3 on one or both alleles compared to those who have the full 
length isoform on both alleles(224). Therefore, for this study, analysis was done with the 
genotypes GY\R-d3/fl and d3/d3 grouped together and also separately (data not shown). We 
acknowledge that the low prevalence of the homozygous d3 (d3/d3) precludes proper study 
of this group.
Despite adequate replacement, patients on rhGH continue to have suboptimal QoL. This 
has been reported in previous studies showing that the QoL scores improve but do not 
normalize and then plateau out after a few years on treatment(126, 167). This is not 
surprising as many of these GHD patients have had surgery and radiotherapy for 
intracranial pathologies and also have multiple hormone deficiencies and are receiving 
other hormone replacements. Also, GHD patients have a significantly higher BMI and fat 
mass than the control population, probably in part due to the metabolic consequences of 
hypothalamic-pituitary disoders(247, 248). Interestingly however, these features also do 
not always revert to normal with hormonal replacement. As expected, there was no 
significant difference in the heights of the volunteers or the patients because GHD was 
mainly of adult onset.
Comparison was made between the different genotypes [///// vs d3/fl and d3/d3~\ for all the 
measured variables in both patients with GHD and in the control population. In the 
patients, this comparison included peak GH levels at diagnosis following glucagon 
stimulation tests, the rhGH dose required to optimize their serum IGF-1 levels, their present 
QoL scores and body composition. There was no significant difference in any of these 
parameters, except for the LFSS between genotypes both with d3 isoform genotypes 
analysed together and separately. The LFSS is a scale that provides the individual an
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opportunity to identify the most important areas of their lives and then ‘Satisfaction with5 
and ‘Impact on’ these areas are then assessed in the subsequent Satisfaction and Impact 
scales.
These data suggest that the polymorphism in exon 3 of the GHR does not influence peak 
GH levels during dynamic pituitary stimulation tests prior to commencement of treatment. 
The polymorphism also does not influence patient response to treatment as determined by 
their QoL scores and body composition. Finally, this polymorphism did not influence the 
extremes of height in the control population in agreement with a previous studies(249). 
Other polymorphisms such as 504A>G at codon 168 of exon 6 and polymorphism 1576 
A>C at codon 526 are common but do not influence response to rhGH treatment in children 
(225). However, the C.1319G>T polymorphism was found to be associated with 
therapeutic efficacy in GHD children (250). Additionally, other genes within the GH 
pathway may also be important, and this relative importance may differ between adults and 
children. Therefore, further studies to investigate genes within and outwith the GH 
pathway are needed. This is important as rhGH is expensive; some patients develop 
adverse effects from therapy, while others show little response. Individualisation of 
therapy in this group of patients therefore is likely to have multiple benefits.
In conclusion, our data show that exclusion of exon 3 in the GHR gene does not influence 
adult height, QoL or body composition in the normal adult control population. Similarly, in 
GHD adults treated with rhGH for >lyear, rhGH dose, QoL and body composition, as well 
as biochemical parameters, were not influenced by GH isoform expressed by the patient. 
Further studies in adult patients with GHD are required to determine the reasons for 
variability in response to rhGH.
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Table 4.1: Underlying diagnosis and previous treatment of patients with GHD
Diagnosis Total Surgery Irradiation Both
Non-functioning
pituitary adenoma
45 42 22 22
Craniopharyngioma 23 19 11 11
Prolactinoma 11 4 3 3
Pituitary apoplexy 4 1 0 0
Rathke’s cyst 3 3 0 0
Astrocytoma 4 2 4 2
Medulloblastoma 4 4 4 4
Miscellaneous 37 20 19 13
Miscellaneous: Cushing’s disease, acromegaly, empty sella syndrome, arachnoid cysts, chordoma,
idiopathic isolated GHD, glioblastoma, thalamic tumour, meningioma, Langerhan ‘s cell 
histiocytosis, HSV encephalitis, pineal tumour, septo-optic dysplasia, nasopharyngeal 
neuroblastoma
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Table 4.2: Other medical conditions and hormone replacement of the GHD patients 
(n=131)
Replacement therapy N (%)
Corticosteroids 92 (68%)
Thyroxine 79 (58%)
Sex Hormones 85 (63%)
DDAVP 28 (21%)
Dopamine Agonists 17(13%)
Total hormone replacement 20(15%)
Coexisting Medical Conditions
Diabetes Mellitus 5 (4%)
Hypertension 36 (27%)
Epilepsy 12 (9%)
Dyslipidaemia 74 (56%)
Previous CVA 6 (5%)
Ischaemic Heart Disease 7 (5%)
Asthma 6 (5%)
Obesity 5 (4%)
Osteoarthritis 4 (3%)
Anxiety/depression 3 (2%)
Severe COPD 2 (2%)
Peripheral Vascular Disease 1 (1%)
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Table 4.3: Comparison of the measured parameters in the patients with GHD between 
d3 genotypes
Measured variables
n
GHR genotype
fl/fl
72
d3/fl or d3/d3
59
p value
Gender (male: female) 37:35 34:25
Age (years) 49 (12) 51 (12) NS
Peak GH (mU/1) 2.7 (3.4) 2.5 (2.2) NS
GH dose (mg) 0.5 (0.6) 0.4 (0.2) NS
Pre-treatment IGF-1 (nmol/1) 13(5) 11(4) NS
Present IGF-1 (nmol/1) 26 (12) 26 (12) NS
QoL
AGHDA 9(6) 11(7) NS
HADS-depression 6(4) 7(5) NS
HADS- anxiety 6(4) 7(5) NS
LFSS 42(4) 41(4) 0.02
Satisfaction scale 25 (5) 25 (5) NS
Disease impact scale 26 (7) 24(7) NS
VAS energy scale (cm) 7.5 (5) 6.0 (2) NS
Measurements
Height (SDS) -0.51 (1.4) -0.23(1.2) NS
BMI (SDS) 2.06(1.1) 2.25 (1.0) NS
WHR 0.92 (0.1) 0.94 (0.1) NS
Body Fat (%) 34.2 (8.8) 35.7(10.2) NS
Significance p<0.05, NS - not significant. Data are presented as mean (SD)
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Table 4.4: Comparison of the measured parameters between the GHD patients and 
controls
Controls
(n=100)
GHD on treatment 
(n=131)
p value
Gender (male:female) 44:56 71:60
Age (years) 45 (13) 50(12) 0.008
QoL
AGHDA 5(6) 10(7) <0.0001
HADS-depresslon 3(3) 7(5) <0.0001
HADS- anxiety 6(4) 6(4) NS
LFSS 43(5) 42(4) 0.02
Satisfaction scale 21(4) 25(5) <0.0001
VAS energy scale (cm) 7.1(2.1) 5.7(2.0) <0.0001
Measurements
Height (SDS) -0.24(1.1) -0.39(1.3) NS
BMI(SDS) 1.22(1.0) 2.14(1.0) <0.0001
WHR 0.87(0.1) 0.93(0.1) <0.0001
Body Fat (%) 29.8(9.5) 34.9(9.5) <0.0001
Significance p<0.05, NS - not significant, Data are presented as mean (SD)
HADS - hospital anxiety and depression scale, LESS- life fulfilment and satisfaction scale, VAS- 
visual analogue scale, BMI- body mass index, WHR- waist-hip ratio.
101
Figure 4.1: The frequency of the different GH receptor polymorphisms in the patient and 
control populations
Controlsn=100 GHDon rhGH n=131
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CHAPTER 5
POLYMORPHISM OF EXON 3 EXPRESSION IN THE CONTROL POPULATION
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Introduction
Adult height distribution in normally growing populations of both sexes presents a wide 
range of variation (23 cm in women and 27 cm in men)(251, 252) and differences between 
populations with different ethnic backgrounds have also been described(253, 254). The 
question arises as to whether the <73/)7~GHR polymorphism would contribute as a factor, 
among others, to explain these differences. Several studies have characterised the 
relationship between the growth hormone receptor exon 3 genotype and the growth 
response in children with short stature or growth hormone deficiency undergoing rhGH 
therapy(3, 223, 224) but only a handful have investigated the relationship between the 
genotype and final adult height in a normal population(255-258). The frequency of this 
polymorphism has been reported in these control cohorts but none have been able to 
conclusively demonstrate an association between the height in an adult control population 
with heights normally distributed (ACPNH) between -2 SD score (SDS) and +2 SDS and 
the exon 3 genotype. There is however evidence to suggest geographical and ethnic 
variations with studies aiming to show the effects of GHR exon 3 genotypes on the height 
differences among populations revealing that the frequency of d3 allele was high among 
the Caucasian population (215, 242, 249), but low in Asian populations (259, 260). Millar 
et al (258) compared an African Beninese population, which has a low mean height, and an 
English population in terms of GHR exon 3 genotype distribution. They observed that the 
Benineses had a significantly higher d3/d3 frequency (47% vs. 28%). Furthermore, d3/fl 
and fl/fl genotypes were also found to be higher among the Beninese than among the 
English population (70% vs. 47%). In this study, we evaluate 100 subjects of both sexes 
with heights normally distributed within normal range, between -2 and +2 SDS.
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Materials and methods
Control Population
A group of 100 healthy volunteers were recruited into the study from the staff of the 
University Hospital Aintree. All the volunteers were white Caucasian adults. They were all 
required to read the Volunteer information Sheet and sign the consent form before 
involvement in the study. The volunteers had no significant past medical history and were 
not on medication that could alter GH secretion. Their body composition was measured and 
the GHR genotypes were determined from a sample of their peripheral blood.
Analysis of the blood sample was carried out as previously described in chapter 2.
QOL questionnaires
QoL was assessed in the control populations using the same 4 validated questionnaires as 
the GHD population. The Adult Growth Hormone Deficiency Assessment (AGHDA) 
questionnaire!; 159), 10-cm Visual Analogue Scale (VAS), the Hospital Anxiety and 
Depression (HADS) questionnaire, the Life fulfilment Scale and the Satisfaction and 
Disease Impact Scale adapted for GHD patients(158). The volunteers were not required to 
fill in the Disease Impact scale questionnaire. The order of completion of questionnaires 
was consistent with the GHD patients and all questionnaires were answered in a single 
session.
Genotyping and Hormone assessment
Genomic DNA was isolated from peripheral blood lymphocytes by standard procedures. A 
35-cycle amplification of the region around exon 3 of the hGHR gene was performed on 
samples using specific primers (GenBank accession no. AF155912I (215) that amplify a
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fragment of 935-bp for fl allele and 532-bp for d3 allele as described in chapter 2. Quality 
control assessment included using positive and negative controls in each batch of samples.
Statistical analysis
Results are expressed as percentages and mean ± SD. Continuous data analysis for a 
difference among the GHRd3IGYfitfl genotypes was calculated using ANOVA (with post- 
hoc Bonferroni correction for multiple testing). Categorical data analysis including the 
GHRd3IG\YRfl allelic and genotype frequencies was performed by the chi-square test. 
Statistical analyses were performed using SPSS 15.0 for Windows.
Results
Population studies and genotype frequencies and Height (SDS) and BMI (SDS) across 
the control population
Of the 100 healthy adult controls, 44% were males with a mean age of 45 (+13) years. The 
frequency of the genotypes was 53% (fl/fl), 40% (d3/fl) and 7% (d3/d3) (table 5.1)
The mean QoL-AGHDA score was 5(+6) and the mean VAS score was 7.1 (+2.1) cm. The 
anxiety and depression scale scores were normal at 6(4) and 3(3) respectively (normal 0-7). 
Measurements of BMI and height were expressed in mean (SD) and standard deviation 
scores (SDS) for normal adult Caucasian population. The mean BMI was 26.45(4.3)kg/m2 
and mean body fat was 29.8(9.5)% (see table 4.4). Further analysis to determine the 
influence of the frequency of the genotypes on these parameters showed no significant 
differences between groups (table 5.2) and on the extremes of height (i.e. SDS<2.0 and 
>2.0); no significant difference in the extremes of height was identified.
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Discussion
In this study, the prevalence of the GHR-d3 polymorphisms in the control population of 
47.9% for fl/fl, 43.6% for d3/fl and 8.5% for d3/d3 was comparable to previous studies 
showing about half of the population being homozygous for the fl allele. In our study, this 
polymorphism did not influence the standard deviation score for the adult height and BMI 
in the control population. This has been demonstrated in previous studies which have also 
not shown correlation between heights of the individuals and GHR isoforms (249, 256). 
Kenth et al (226) reported a GHR exon 3 genotype distribution similar to our study, and 
they also failed to demonstrate an association between the adult height and GHR genotype. 
Raz et al (227) investigated GHR exon 3 genotype distribution in 211 Swiss adults with 
normal stature. As in our study, there was no significant difference in final adult height and 
height-SDS according to the exon 3 genotypes.
The adult height population evaluated by us included a fairly even distribution of subjects 
of both sexes with heights normally distributed within normal range, between -2 and +2 
SDS and as with similar studies, no statistically significant differences in mean height-SDS 
values among the three GHRd3 genotypes could be found. Whilst our study did not 
measure the serum IGF-1 of the control population to determine its relationship to the 
height SDS and GHR isoforms, recent evidence shows that there were no differences in 
genotypes, IGF-1 and IGF binding protein-3 (IGFBP-3) SDS values among control 
subjects grouped according to their height SDS(256).
Adult height is not determined by a single gene but by complex polygenic inheritance. 
Studies in adult twins have shown that differences in height are related by 75-89% to 
genetic factors (261, 262). Genetic influences on birth length and postnatal growth are still 
being studied(241). Genome-wide analysis is expected to facilitate the discovery of new 
genes related to somatic growth and to reveal the extent of impact of known genes. GHR
107
exon 3 genotypes constitute the first genetic factor shown to affect the response to GH 
therapy(3).
Another potential effect of this polymorphism of the GHR has been studied in non-GHD 
populations. A recent study in a Chinese obese population without GHD reports that the 
exon 3 GHR polymorphism has a significant effect on BMT with the d3 allele 
demonstrating a protective effect on the development of metabolic syndrome by increasing 
insulin sensitivity (240). Similar results were also reported in 2008 by Binder et al(242) 
where d3/d3 allele was associated with weight regulation towards a lower BMI in patients 
with Turner’s syndrome.
Further studies are required to determine the significance, if any, of this polymorphism of 
the GHR in healthy populations.
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Table 5.1: Frequency of genotypes in the control population
Genotype Controls
n=100
fl/fl 53%
d3/fl 40%
d3/d3 7%
Table 5.2: Comparison of anthropometric measurements and BC between genotype groups in 
the control population
Measured variables
GHR genotype
fl/fl d3/fl or d3/d3 p value
Frequency 53% 47%
Height (SDS) -0.22(1.1) -0.23(1.1) ns
BMI(SDS) 1.25(1.0) 1.23(1.02) ns
Body Fat (%) 29.9(9.5) 29.8(9.4) ns
Significance p<0.05, NS - not significant, Data are presented as mean (SD)
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CHAPTER 6
FINAL DISCUSSION AND STUDY SUMMARY
GENERAL DISCUSSION
For GHD adults in the United Kingdom, apart from biochemical evidence of severe GHD, 
the decision to commence and continue treatment are based on the demonstration of 
impaired QoL from NICE approved validated questionnaires. Two main sets of GHD 
patients are seen in our adult clinic population; a treated group on rhGH and an 
asymptomatic group not requiring GH replacement therapy.
Despite several recent publications in the paediatric population, there have been few 
publications studying the role of polymorphisms in the GHR gene and response to GH 
therapy in the adult population. Similar studies investigating the exon 3 polymorphism in 
the adult population (4, 246) did not address QoL, the main indication for the use of rhGH. 
Exon 3 polymorphism in these GHD adults was not predictive of biochemical and 
hormonal response to rhGH therapy so the controversy still exists as to the role of the 
GHRd3 polymorphism on the response of GHD patients to treatment. Some studies in 
children have demonstrated a superior growth velocity in individuals with the d3 isoform 
(3, 224, 241) while other studies report there is no significant difference between these 
groups (222, 225). We hypothesized that adult GHD patients with exon 3 deletion are less 
likely to be symptomatic from GHD than those without.
This project aimed to determine the prevalence of the polymorphism of exon 3 of the GHR 
in the local population and also to analyze the impact of the genotypes GHR-t/54/3, GHR- 
dS/Jl, and GHR-///// on response to treatment with rhGH in GHD adults. We therefore 
studied the relationship between QoL, the qualification for rhGH therapy using NICE 
criteria and deletion of exon 3 in the GHR gene. We also investigated the relationship 
between exon 3 deletion and other markers of GHD: serum IGF-1 prior to rhGH therapy 
and anthropometric measures.
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A few studies in adults with GHD using a variety of QoL instruments have shown multiple 
impairments in QoL in untreated GHD adults compared to control adults. Many studies 
have also shown improvement in QoL measures especially energy levels and psychological 
well-being in the first 2-3 years following rhGH replacement (126, 171, 184). However, a 
few studies have failed to demonstrate this improvement (222, 225). This could be because 
the QoL was measured using non-specific psychometric instruments (200, 209). In studies 
in which questionnaires designed specifically for GHD have been used to assess QoL, 
improvements with rhGH therapy have been consistently reported (158, 263, 264) such as 
disease specific health related QoL questionnaire previously designed in this unit for use in 
GHD patients (158).
An interesting group of patients in whom data is lacking are the GHD patients without 
impairment in QoL scores. These asymptomatic GHD patients do not seem to require 
treatment with rhGH according to present treatment guidelines as their QoL scores are 
comparable to those of health controls (see chapter 3).
The prevalence of the three GHR-d3 genotypes in the population we studied was 
comparable to previous studies in which up to half of the population is homozygous for the 
fl allele(221, 242, 243). As previous studies in children suggest that patients who delete 
exon 3 on one or both alleles (d3/fl and d3/d3) have a similar growth response to rhGH, 
data from these patients were analysed together and separately. The results of our study do 
not support our original hypothesis that patients with the d3/fl or d3/d3 genotype are less 
likely to need rhGH therapy to improve quality of life than those with the fl/fl genotype.
The difference in depression scale between the two genotype groups is probably of no 
clinical significance because scores of 0 to 7 on the HADS-depression scale are classed as 
normal with 8 to 10 being borderline normal and 11 to 21 being abnormal(237). Data from
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this project also suggest that the GHR-d3 polymorphism does not influence body 
composition neither stimulated GH levels during provocative testing prior to rhGH therapy. 
A total of 100 healthy Caucasian adults were studied and the prevalence of the GHR-d3 
polymorphisms was comparable to previous studies showing up to half of the population 
being homozygous for the fl allele. Similar frequencies were also seen in the GHD patient 
population. Previous studies have shown that growth response in GHD children is greater 
in children who exclude exon 3 on one or both alleles compared to those who have the full 
length isoform on both alleles(224). Therefore, for this study, analysis was done with the 
genotypes GHK-d3/fl and d3/d3 grouped together and also separately. We acknowledge 
that the low prevalence of the homozygous d3 (d3/d3) precludes proper study of this group. 
This thesis suggests that in the adult population with GHD factors other than the GHR-d3 
polymorphism influence the QoL. There are multiple causes of hypopituitarism in GHD 
adults and patients receive multiple and prolonged treatments, attending regular and 
repeated follow-up MRI/CT scanning which, in themselves, generate anxiety. As a result, 
determinants of QoL in adults are probably multi-factorial and may in fact be difficult to 
relate to a single cause such as the GHR-d3 polymorphism. Coexisting medical conditions 
are also likely to impact on QoL. It is also important to observe that while in children, 
response to treatment is easily measured by growth velocity, QoL measures remain the best 
way of monitoring response to treatment in adults with GHD. However in many patients, 
QoL is difficult to measure and interpret, and may lack sensitivity.
The data show that despite adequate hormone replacement, patients on rhGH continue to 
have suboptimal QoL. This has been reported in previous studies showing that the QoL 
scores improve and then plateau after a few years on treatment (126, 167). This is not 
surprising as many of these GHD patients have had surgery and radiotherapy for 
intracranial pathologies and also have multiple hormone deficiencies and are receiving
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other hormone replacements. Also, GHD patients have a significantly higher BMT and fat 
mass than the control population, probably in part due to the metabolic consequences of 
hypothalamic-pituitary disorders (247, 248). Interestingly however, these features also do 
not always revert to normal with hormonal replacement. As expected, there was no 
significant difference in the heights of the volunteers or the patients because GHD was 
mainly of adult onset.
To date, results relating the GHRd3 polymorphism and growth hormone response are 
inconclusive. Newer studies have demonstrated that GHRc/3 polymorphism has a 
significant effect on BMI and the metabolic parameters in obese children (240). This is a 
growing are of interest and further studies are needed to investigate this and other 
polymorphisms in both children and adults with or without GHD. In conclusion, we have 
demonstrated that the deletion of exon 3 in the GHR gene does not influence QoL and 
energy levels in adults with GHD.
These data suggest that the polymorphism in exon 3 of the GHR does not influence adult 
height, QoL or body composition in the normal adult control population nor the extremes 
of height in the control population in agreement with a previous study(249). It does not 
influence peak GH levels during dynamic pituitary stimulation testing prior to 
commencement of treatment. The polymorphism also does not influence patient response 
to treatment as determined by their QoL scores and body composition. Similarly, in GHD 
adults treated with rhGH for >lyear, rhGH dose, QoL and body composition, as well as 
Ibiochemical parameters, were not influenced by GH isoform expressed by the patient. 
Recent studies have investigated the effect of the polymorphism of exon 3 of the GHR on 
metabolic parameters such as systolic blood pressure and BMI in obese (240), Turner’s 
(242) and acromegalic populations (265) with conflicting results.
115
Other polymorphisms such as 504A>G at codon 168 of exon 6 and polymorphism 1576 
A>C at codon 526 are common but do not influence response to rhGH treatment in children 
(225). However, the C.1319G>T polymorphism was found to be associated with 
therapeutic efficacy in GHD children (250). Additionally, other genes within the GH 
pathway may also be important, and this relative importance may differ between adults and 
children. Therefore, further studies to investigate genes within and outwith the GH 
pathway are needed. This is important as rhGH is expensive; some patients develop 
adverse effects from therapy, while others show little response. Individualisation of 
therapy in this group of patients therefore is likely to have multiple benefits.
The stimulus to embark on long-term GH replacement is likely to come from the patient 
rather than the clinician, and this decision might ultimately be made on the basis of any 
benefits experienced by the patient during a trial period of GH replacement.
There is an argument however that because GH replacement in adults has physical and 
biochemical effects that may be considered by a clinician to be beneficial, a patient may 
not necessarily perceive these benefits and none of these effects currently constitute an 
absolute indication for GH replacement (266). Until a time when these effects might be 
shown to be beneficial to the patient in the long term (for example, a reduction in mortality 
from cardiovascular disease or a sustained increase in bone mineral density associated with 
a decrease in incidence of bone fracture), the indication for GH replacement in adults is 
likely to be the improvement in well-being that many patients experience whilst on 
treatment(163).
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APPENDIX 1
QoL-AGHDA
Quality of Life Assessment of GH Deficiency in Adults
QOL-AGHDA English 2000-02-17 OR 706-1-01
LISTED BELOW ARE SOME STATEMENTS that people may make about themselves. 
Read the list carefully and put a tick a box marked YES if it applies to you.
Tick the box marked NO if it does not apply to you
Please answer every item. If you are not sure whether to answer YES or NO, tick 
whichever answer you think is most true in general.
I have to struggle to finish jobs 
I feel a strong need to sleep during the day 
I often feel lonely even when I am with people 
I have to read things several times before they sink in
YES NO
It is difficult for me to make friends 
It takes a lot of effort for me to do simple tasks 
I have difficulty controlling my emotions 
I often lose track of what I want to say
I lack confidence 
I have to push myself to do things 
I often feel very tense
I feel as if I let people down
I find it hard to mix with people
I feel worn out even when I’ve not done anything
There are times when I feel very low 
I avoid responsibilities if possible 
I avoid mixing with people I don’t know
I feel as if I’m a burden to people 
I often forget what people have said to me 
I find it difficult to plan ahead 
I am easily irritated by other people
I often feel too tired to do things that need doing 
I often have to force myself to stay awake 
My memory lets me down
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APPENDIX 2
The Life Fulfilment Scale Adapted For Growth Hormone Deficiency
Listed below are various aspects of life. People disagree about how important each aspect 
is. We would like to know how important you feel each aspect to be, regardless of whether 
or not it applies to you personally.
For each item, please circle the number which indicates your feelings about the importance 
of that item. For example, if you feel that a good family is very important, circle 4: if you 
think it is fairly important, circle 3; and so on.
Please answer all the items.
Very
important
Fairly
important
Not very 
important
Not at all 
important
a) A good family life 4 3 2 1
b) Having close friends you can confide 
in
4 3 2 1
c) Being able to do things you enjoy in 
your spare time
4 3 2 1
d) Enjoying a good social life 4 3 2 1
e) Being in good health 4 3 2 1
0 Being happy with yourself as a 
person
4 3 2 1
g) Being happy with the area where you 
live
4 3 2 1
h) Having housing which meets your 
needs
4 3 2 1
i) Having an adequate standard of 
living
4 3 2 1
j) Having enough money to do most of 
the things you want to do
4 3 2 1
k) Being happy with your appearance 4 3 2 1
1) A fulfilling sexual relationship 4 3 2 1
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Satisfaction Scale
Now we would like to know how satisfied you are with your own life.
For each question below, please circle the number which shows best how you feel. 
Please answer every question.
1) How satisfied are you, in general, with your life?
a) Very satisfied........................................................................... 1
b) Satisfied................................................................................... 2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied......................................................................4
2) How happy do you feel about the number of close friends you have - that is friends 
you feel you can confide in?
a) Very happy.............................................................................. 1
b) Fairly happy............................................................................ 2
c) Not very happy........................................................................3
d) Not at all happy.......................................................................4
3) How much do you feel able to do things you enjoy in your spare time?
a) Often..................................................................  l
b) Sometimes..............................................................................2
c) Rarely..................................................................................... 3
d) Never...................................................................................... 4
4) How satisfied are you, in general, with your social life?
a) Very satisfied............................................................................1
b) Satisfied..... .............................................................................2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied......................................................................4
5) How would you describe your health now?
a) Excellent.................................................................................. 1
b) Good........................................................................................ 2
c) Fair........................................................................................... 3
d) Poor........................................................  4
6) How happy are you with the way you feel about yourself?
a) Very happy.............................................................................. 1
b) Fairly happy.............................................................................2
c) Not very happy........................................................................ 3
d) Not at all happy....................................................................... 4
7) How satisfied are you in general with the area that you live?
a) Very satisfied........................................................................... ]
b) Satisfied............................................................  2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied...................................................................... 4
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8) How satisfied are you in general with your present housing condition?
a) Very satisfied............................................................................1
b) Satisfied........ .......................................................................... 2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied......................................................................4
9) How satisfied are you with your present standard of living?
a) Very satisfied............................................................................1
b) Satisfied................................................................................... 2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied......................................................................4
10) How satisfied are you with the amount of money you have coming in?
a) Very satisfied................................................................... .
b) Satisfied.............................................................................
c) Dissatisfied.......................................................................
d) Very dissatisfied
.1
2
3
4
11) How satisfied are you with your sexual relationship?
a) Very satisfied........................................................................... 1
b) Satisfied................................................................................... 2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied......................................................................4
12) How satisfied are you with your appearance?
a) Very satisfied............................................................................1
b) Satisfied................................................................................... 2
c) Dissatisfied.............................................................................. 3
d) Very dissatisfied...................................................................... 4
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Impact Scale
We would like to know how much you feel your condition and its treatment affects 
your everyday life.
For each item listed, please circle the number which shows best how you feel.
1) Your relationship with your spouse/partner?
a) A lot............................................................................................ 1
b) Some........................................................................................... 2
c) A little......................................................................................... 3
d) Not at all..................................................................................... 4
e) Does not apply (no spouse/partner).......................................... 5
2) Your relationship with other close members of your family?
a) A lot............................................................................................ 1
b) Some........................................................................................... 2
c) A little......................................................................................... 3
d) Not at all..................................................................................... 4
3) Your social life and activities?
a) A lot............................................................................................ 1
b) Some...............................................  2
c) A little..........................................................................................3
d) Not at all..................................................................................... 4
4) Whether or not you are able to work in paid employment?
a) A lot............................................................................................ 1
b) Some............................................................................................2
c) A little..........................................................................................3
d) Not at all..................................................................................... 4
e) Does not apply (not working).................................................. 5
5) The kind of paid work you can do?
a) A lot............................................................................................ 1
b) Some............................................................................................2
c) A little..........................................................................................3
d) Not at all................  4
e) Does not apply (not working)...................................................5
6) Your health overall?
a) A lot............................................................................................ 1
b) Some............................................................................................2
c) A little..........................................................................................3
d) Not at all..................................................................................... 4
7) Your relationship with friends?
a) A lot............................................................................................ I
b) Some............................................................................................2
c) A little..........................................................................................3
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d) Not at all 4
8) The way you feel about yourself?
a) A lot............................................................................................ 1
b) Some............................................................................................2
c) A little..........................................................................................3
d) Not at all..................................................................................... 4
9) Your plans and ambitions for the future?
a) A lot............................................................................................. 1
b) Some........................................................................................... 2
c) A little..........................................................................................3
d) Not at all..................................................................................... 4
10) Standard of living?
a) A lot............................................................................................ 1
b) Some............................................................................................2
c) A little..........................................................................................3
d) Not at all...............................  4
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APPENDIX 3
Visual Analogue Scale for Energy Levels
How much energy do you feel you have today?
Place a vertical line on the on the scale below to indicate how much energy you have today.
No energy Full of energy
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APPENDIX 4
The Hospital Anxiety and Depression Scale (HADSI
You are being asked to choose one response from the four given. You are required to give 
an immediate response and not dwell too long about their answers.
The questions relating to anxiety are marked ‘A* and to depression marked ‘D’
The score for each answer is given in the right column.
Please circle the most appropriate answer.
Please answer all questions
A I feel tense or 'wound up':
Most of the time 3
A lot of the time 2
From time to time, occasionally 1
Not at all 0
D I still enjoy the things I used to enjoy:
Definitely as much 0
Not quite so much 1
Only a little 2
Hardly at all 3
a I a S0|T of frightened feeling as if something awful is about to 
happen:
Very definitely and quite badly 3
Yes, but not too badly 2
A little, but it doesn't worry me 1
Not at all 0
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D I can laugh and see the funny side of things:
As much as I always could 0
Not quite so much now 1
Definitely not so much now 2
Not at all 3
A Worrying thoughts go through my mind:
A great deal of the time 3
A lot of the time 2
From time to time, but not too often 1
Only occasionally 0
D I feel cheerful:
Not at all 3
Not often 2
Sometimes 1
Most of the time 0
A I can sit at ease and feel relaxed:
Definitely 0
Usually 1
Not Often 2
Not at all 3
D I feel as if I am slowed down:
Nearly all the time 3
Very often 2
Sometimes 1
Not at all 0
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A I get a sort of frightened feeling like 'butterflies' in the stomach:
Not at all 0
Occasionally 1
Quite Often 2
Very Often 3
D I have lost interest in my appearance:
Definitely ’ 3
I don't take as much care as I should 2
I may not take quite as much care 1
I take just as much care as ever 0
A I feel restless as I have to be on the move:
Very much indeed 3
Quite a lot 2
Not very much 1
Not at all 0
D I look forward with enjoyment to things:
As much as T ever did 0
Rather less than I used to 1
Definitely less than I used to 2
Hardly at all 3
A I get sudden feelings of panic:
Very often indeed 3
Quite often 2
Not very often 1
Not at all 0
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D I can enjoy a good book or radio or TV program:
Often 0
Sometimes 1
Not often 2
Very seldom 3
Scoring
(Add the As = Anxiety. Add the Ds =:: Depression). The norms below will give you 
idea of the level of Anxiety and Depression.
0-7 = Normal
8-10 — Borderline abnormal
11-21 = Abnormal
APPENDIX 5
Patient Information Leaflet
1 Introduction
We would like to invite you to take part in a research study being conducted at the 
University Hospital Aintree. This is absolutely voluntary and if after reading this 
information leaflet, you decide not to participate, your decision will be accepted without 
question. Your treatment will not be affected in any way if you decide not to take part in 
the study.
This information sheet describes the study and what it would mean for you if you decide to 
participate.
2 What is the purpose of the study?
There is some evidence to suggest that the response to GH therapy in patients who are 
deficient of this hormone may be determined by our genes (the basic building blocks of 
life). The type of gene you express may determine how severe your symptoms are and how 
well you respond to the replacement treatment and how much GH you will require to get 
reasonable response. It is likely that knowing which genotype you belong to will help you 
and others like you to quickly determine the dose and of GH required for therapy instead of 
long months of titrating therapy. The purpose of this study is to identify polymorphism of 
this gene and to compare it with changes in your body composition and QoL. We require 
your permission to be able to test for this gene.
3 Why have I been chosen ?
You have been chosen for the study because you are deficient in a hormone called growth
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hormone. Growth hormone stimulates growth in children but for fully grown adults who 
are deficient in this hormone, it alters body composition, their general well-being and 
energy levels. We need to recruit a large number of patients such as yourself. It is likely 
that about 400 will be required. In view of this, we consider this to be a long-term study 
lasting up to 2years.
4 Who is organising the study?
This is a joint study between the endocrine clinic at the University Hospital Aintree and the 
University of Liverpool.
What mil happen to me if I participate?
If you decide to participate in this study, an extra 1 Omls (equivalent to two teaspoons-full) 
will be taken when you have your routine blood taken for tests at the clinic. Taking a blood 
tests is a routine procedure with minimal risks such as minor discomfort at the time of 
taking blood and bruising. You will be required to answer standardised questionnaires, one 
of which is routinely administered for all patients with laboratory evidence of growth 
hormone deficiency according to NICE guidelines. We will also require some data relating 
to previous blood test results from your notes (the information we need is detailed in the 
attached proforma).
When starting GH replacement therapy for the first time, regular routine blood tests are 
done to determine your response to GH therapy until normal levels of GH in the blood is 
reached. Participants will also have repeat questionnaires administered to determine their 
QoL after normalization of their blood test. Both the blood tests and questionnaires are 
normal routine procedure for all patients on GH therapy. For the purpose of this study 
however, additional questionnaires will be administered to the routine questionnaire filled
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before and after optimizing treatment with GH.
What are the possible benefits of taking part?
Determination of the polymorphism of the GHR gene as it relates to response to GH 
therapy may not benefit you directly. It may however help future GH deficiency patients to 
determine who is likely to respond to therapy and the dose of GH most appropriate for 
which genotype of GHR gene. GHR gene polymorphism maybe then be routinely checked 
before commencing therapy. This will prevent delay in reaching normal GH levels in the 
blood, prevent repeated blood tests and make funding more easily available for the patients 
who are most likely to benefit from therapy.
What are the possible risks of taking part?
The extra 10ml of blood taken from your routine tests will not cause any significant 
problems as your body normally contains about 5 litres of blood (5000ml). All your results 
will be kept completely confidential and it will not be possible to link your results to you, 
so there will be NO effect on you (or your family's) ability to obtain any kind of insurance.
What will happen to my blood test?
Your blood sample will be stored in a locked freezer in the University Hospital Aintree 
and/or the University of Liverpool. It is important to note that the stored blood samples and 
any notes relating to it will be identified only by a code number, and therefore it will not be 
possible to trace the blood sample back to you by persons not involved with the study. We 
will keep your sample until all of it is used up.
Your blood sample will be considered to be a gift to the University Hospital Aintree, which 
will act as custodian of all the samples obtained as part of this project. In some cases, a
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small amount of your sample will be provided to other researchers either in the UK or other 
parts of the world. However, it is important to remember that this will only be identified by 
a code number.
In the short-term, it is unlikely that the samples will be of any commercial value to the 
Trust. However, it is possible that there may be some commercial value in the future, 
although it is important to note that any commercial value is likely to be due to findings in 
a group of patients rather than from samples from a single patient.
Confidentiality - who will know I am taking part in the study?
As stated above, your sample will be anonymised, and therefore the genetic information 
obtained from it will be kept strictly confidential and will only be available to the study 
doctors. Other nominated members of the study can only access this on written request to 
you. If you would require your GP be involved about your participation in the study, we 
willdo so in writing. We will disclose individual results to yourself and your GP only with 
your permission.
We will combine all the results from the many patients taking part in the study, and publish 
any important results in medical journals.
Contact for further information
If you need further information or are worried about any aspect of the study, please do not 
hesitate to contact Dr ‘Lara Adetunji, Research Fellow University Hospital Aintree on 0151 
529 6146 or Dr I.A. MacFarlane, Consultant Physician University Hospital Aintree on 
0151 529 4650.
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RESEARCH PARTICIPANT CONSENT FORM
Patient study ID Number______________
I FREELY AGREE TO PARTICIPATE IN THIS STUDY Yes No
I have read the Patient Information Sheet provided Yes No
I have had the opportunity to ask questions about the study Yes No
I understand that my medical care will not be affected if I Yes No
do not participate in the research study.
I give consent for my case records to be looked at if Yes No
necessary for purposes of the study.
I can withdraw at any time without giving a reason Yes No
I give permission for my GP to be informed Yes No
Name and signature of Participant:
.......................................................................................................... Date:
Name and signature of Principal/Local Investigator:
.......................................................................................................... Date:
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5 GP/CONSULTANT INFORMATION LETTER
Dear Doctor
Your patient................................................................  who has growth hormone deficiency
has consented to participate in a study to identify the polymorphism of the growth hormone 
receptor gene. This study will involve adult patients from age of 16yrs onwards attending 
the neuroendocrine clinic under Dr LA. MacFarlane. Blood tests will be taken to determine 
polymorphism of genomic DNA that encodes for growth hormone receptor gene. Quality 
of life questionnaires will also be administered to your patient before and after optimising 
therapy with GH. Your patient can withdraw at any time without giving an explanation. 
Your patient has been given an information leaflet and informed consent has been taken.
If you require any further information, please contact the local investigator, Dr Omolara 
Adetunji Tel: 0151 529 6146 or the Chief Investigator, Dr Ian MacFarlane, Tel: 0151-529- 
4650.
Yours faithfully 
Dr ‘Lara Adetunji
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APPENDIX 6
Volunteer Information sheet
6 Introduction
We would like to invite you to take part in a research project. This is absolutely voluntary 
and if when you have heard about the study, you would prefer not to participate, your 
decision will be accepted without question. This is an information sheet, which describes 
the project and what it would mean for you if you did participate.
7 What is the purpose of the study?
There is evidence to suggest that about one half of the human population have differences 
in the gene (building blocks of the body) that determines the function of the growth 
hormone receptor. Whilst this difference does not affect the growth and development of the 
population, it affects how patients with growth hormone deficiency respond to treatment. 
The purpose of this study is to identify how common these different genes are in the 
normal local population (such as yourself) and compare this to the frequency in a 
population of patients with deficiency of growth hormone.
8 Why have I been chosen ?
You have been chosen at random for this study because your age and sex match those of 
the patients involved in the study.
9 Who is organising the study ?
The study is being organised by the University Hospital Aintree NHS trust and the 
University of Liverpool.
What will happen to me if / take part?
If you decide to participate you will be asked to provide between 10ml of blood (equivalent 
to two teaspoons-full). You will be asked to answer questionnaires pertaining to your 
energy levels along with some basic measurements to check your weight, height, hip and 
waist measurements and your body’s percentage fat mass. Taking blood tests is a routine 
procedure with minimal risks such as minor discomfort at the time of taking blood and 
bruising.
What will happen to my blood test?
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Your blood sample will be stored in a locked freezer in the University Hospital Aintree. 
We will isolate DNA from your blood sample, which will then be used to analyze genes 
involved in the control of the growth hormone receptor. It is important to note that the 
DNA isolated from the blood sample and any notes relating to it will be identified only by a 
code number initially. Once this has been done, your sample will be irretrievably 
anonymised at which time it will not be possible to trace the blood sample back to you. We 
will keep your sample until all of it is used up.
Your blood sample will be considered to be a gift to the University Hospital Aintree, which 
will act as custodian of all the samples obtained as part of this project. In some cases, a 
small amount of your sample will be provided to other researchers either in the UK or other 
parts of the world. However, it is important to remember that only a code number will 
identify this.
In the short-term, it is unlikely that the samples will be of any commercial value to the 
Trust. However, it is possible that there may be some commercial value in the future, 
although it is important to note that any commercial value is likely to be due to findings in 
a group of patients rather than from samples from a single patient.
What are the possible benefits of taking part?
You will not receive any financial or therapeutic benefit from taking part in the study. 
However, the knowledge gained from this study may go a long way to help patients with 
growth hormone deficiency in the future.
What are the possible risks of taking part?
There may be some minor but short-lasting discomfort from having a blood test. Since all 
your results will be kept completely confidential, and it will not be possible to link your 
results to you, there will be NO effect on your (or your family’s) ability to obtain any kind 
of insurance.
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Confidentiality - who will know lam taking part in the study?
As stated above, your sample will be anonymised, and therefore the genetic information 
obtained from it will be kept strictly confidential and not be disclosed to anyone. We will 
not disclose individual results to yourself, your GP or your hospital doctor. We will 
combine all the results from the many participants taking part in the study, and publish any 
important results in medical journals.
Contact for further information
If you need further information or are worried about any aspect of the study, please do not 
hesitate to contact Dr ‘Lara Adetunji, Research Fellow University Hospital Aintree on 0151 
529 6146 or Dr I.A. MacFarlane, Consultant Physician University Hospital Aintree on 
0151 529 4650.
THANK YOU FOR READING THIS LEAFLET.
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RESEARCH PARTICIPANT CONSENT FORM
Volunteer study ID Number
I FREELY AGREE TO PARTICIPATE IN THIS STUDY 
I have read the Volunteer Information Sheet provided 
I have had the opportunity to ask questions about the study
YesD NoD
YesD NoD
YesD NoD
Signature of Participant:
Date:
Name and signature of Principal/Local Investigator:
Date:
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APPENDIX 8: Some pictures of amplified GHRd3 alleles following electrophoresis
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